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1. Introduction 
Cardiovascular disease is one of the leading causes of death in western societies, 
and accounts for 1 in every four deaths in the United States [1]. Under this 
umbrella are several conditions, with a large subset related to atherosclerosis. This 
condition, characterized by the build-up of plaque in the arteries throughout the 
life of individuals, creates narrowing that can impede blood flow, but also cause 
heart attacks or strokes when these plaques release material in the blood stream 
that leads to clotting and complete obstruction of downstream arteries. Total 
coronary occlusion leads to cell death in the myocardium if blood flow is not 
restored shortly, by means of either thrombolytic therapy or percutaneous 
coronary intervention (PCI).  
When atherosclerosis manifests itself by a stable reduction of blood flow, it leads 
to symptoms such as chest pain, discomfort or shortness of breath, and is easily 
diagnosed by clinicians. In this case, blood flow can typically be restored by PCI 
with the apposition of stents - metal or polymer scaffoldings - that support the 
narrowed vessel and restore sufficient cross section. Unfortunately, many patients 
are diagnosed with cardiovascular disease only when subject to a heart attack. This 
is due to atherosclerotic lesions that do not present a clinically significant lumen 
narrowing, such that a plaque rupture or erosion happens before any other 
symptoms that can lead to identification of the disease. 
There currently isn’t any reliable way to determine which patients are likely to 
experience acute myocardial infarction (AMI). Even for patients that have been 
subject to AMI, determining which lesions are likely to cause future event is 
challenging with current tools. Therefore, development of imaging techniques able 
to better characterize atherosclerotic disease may change patient care and lead to 
improvements in public health.  
At the research level, the current understanding of the development of 
atherosclerotic diseases is based on retrospective autopsy studies as well as 
preclinical work in cell and animal models. The development of laboratory models 
that fully capture the complexity of a disease that evolves over decades is 
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challenging, and in situ investigation of atherosclerosis in patients is limited to a 
few imaging techniques, either full body or catheter based, that only provide 
limited information.  
Therefore, clinical practice, development and evaluation of new therapeutic 
options, and basic research about atherosclerosis development would benefit from 
improved characterization techniques suitable for in vivo use.  
1.1 Medical	imaging	
When performing diagnostics on patients, medical practitioners gather 
information through a variety of techniques. Some are basic, such as description of 
the symptoms by the patient, body temperature measurement, palpation, and have 
been used since the early days of medicine. Advances in science and technology 
have opened the way to new approaches, such as the analysis of bodily fluids (such 
as blood or urine samples), measurement of body functions (such as 
electrocardiography), tissue level diagnostics (histology), or medical imaging.  
Medical imaging consists of creating visual representations of areas of the body 
that are not accessible via direct examination. It can for example reveal internal 
structures or functions and is a key component for the diagnostic and treatment of 
diseases.  Most imaging techniques used in the clinical practice are non-invasive, 
meaning that the imaging instrumentation is outside of the patient’s body. The 
most commonly used are radiography, ultrasound (US), magnetic resonance 
imaging (MRI), and computed tomography (CT). These techniques are 
complemented by less common methods such as nuclear imaging. 
The choice of imaging technique depends on a variety of factors, namely safety, 
cost, ability of the contrast mechanism to provide relevant information to the 
medical practitioner. Not surprisingly, two of the most widespread medical 
imaging techniques, projectional radiographs (X-rays) and ultrasound are low cost, 
present negligible risks, and provide great insight into the body’s interior 
structure. When alternative methods do not provide the level of information 
required for proper diagnostics, clinical practitioners will direct patients to 
imaging modalities such as MRI, CT, or nuclear imaging  (positron emission 
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tomography or single photon emission computed tomography) that are more costly 
or present exposure to ionizing radiation. Finally, injection of high attenuation (e.g. 
iodinated) contrast agent can be combined with projectional radiographs and CT 
to address the lack of soft tissue contrast, leading to Fluoroscopy also known as X-
ray angiography, and contrast enhanced CT respectively. A summary of these 
clinical non-invasive imaging techniques is provided in table 1. 
 
Imaging Modality Advantages Drawback 
Projectional 
radiography 
 Low cost 
 low dose 
 high spatial resolution 
 2D only 
 no soft tissue contrast 
 No molecular contrast 
Ultrasound  Low cost 
 No exposure to ionizing 
radiation  
 Real time image display 
 Trade-off between penetration 
depth and spatial resolution 
 No molecular contrast 
CT  High spatial resolution 
 3D images 
 Significant radiation exposure 
(10 mSv) 
 No soft tissue contrast 
MRI  3D images 
 No exposure to ionizing 
radiation  
 Soft tissue contrast 
 Limited spatial resolution 
 Limited acquisition speed 
 Cost 
PET/SPECT  Molecular contrast   Requires suitable radiotracer  
 Exposure to ionizing radiation  
(25 mSv for PET) 
 Cost 
Fluoroscopy  High spatial resolution 
 Visualization of vessel lumen 
 2D only 
 Significant radiation exposure 
for multiple image acquisition 
 Use of potentially harmful 
contrast agent 
Contrast enhanced CT  High spatial resolution 
 Visualization of vessel lumen 
 3D images 
 Significant radiation exposure 20 
mSv 
 Use of potentially harmful 
contrast agent 
Table 1: Description of non-invasive imaging modalities  
 
The availability of non-invasive imaging techniques has enabled breakthroughs in 
clinical decision making. Nevertheless, limitations in acquisition speed, contrast 
and spatial resolution mean that imaging of specific conditions is still out of reach 
from these modalities. Atherosclerosis, described in the following section, is one of 
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such conditions, and thus requires the development of alternate imaging 
approaches.  
1.2 Basics	of	Atherosclerosis	
The development of plaque, called atherogenesis, consists of a remodeling of the 
arteries that includes accumulation of lipids under the endothelium. This process 
is slow and progresses over the entire lifespan of individuals, starting during 
childhood, and typically does not lead to symptomatic manifestations before 
middle-age [2]. The development of lesions is complex and still not fully understood 
after decades of research but is thought to proceed in the following manner.  
Circulating low density lipoprotein (LDL) particles accumulate in the endothelium 
and undergo oxidation via enzymatic action, leading to an inflammatory response. 
In turn, circulating monocytes are drawn into the sub-endothelial space and 
differentiate into macrophages [3]. When oxidized LDL gets ingested by 
macrophages, numerous small lipid inclusions develop into the cytoplasm. They 
increase in size and turn into macrophage foam cells (mFC). These mFC 
accumulations, called fatty streaks, may progress into advanced lesions but also 
regress on their own [2]. The path to more advanced lesions is understood to be 
driven by apoptosis of these foam cells that release cholesterol in the extracellular 
space and promote further inflammation. The rate of accumulation of free 
cholesterol in the endothelium is influenced by the protective effect of high-density 
lipoproteins (HDL), able to transport cholesterol back into the bloodstream and 
ultimately to the liver and other organs.   
Early fibroatheroma, characterized by the apparition of extracellular lipid pools 
and decreased cellularity, is considered the first step of atherosclerosis. In that 
phase, characterized by high levels of inflammation, smooth muscle cells (SMC) 
secrete proteoglycans in the extracellular space. Lipids bind to these proteoglycans 
with high affinity and continue to accumulate [4]. The creation of lipid pools leads 
to mFC and SMC apoptosis, thus generating necrotic debris that increase 
inflammation. Fibrous tissue also develops close to the endothelium and lead to 
the typical fibrous plaque lesion, with a lipid-rich necrotic core.  
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Figure 1: Illustration of different stages of development of atherosclerosis. Endo dysfunction Athero, CC BY-
SA 3.0 
 
It can be noted that the increase in plaque thickness does not necessary correspond 
to a reduction in vessel cross section (stenosis) as media and adventitia are also 
impacted and expand in a process called outward remodeling. Outward remodeling 
enables plaque burden accumulation while remaining clinically silent. 
In later stages of the disease, enzyme activity degrades the fibrous tissue, and 
leads to thin cap fibroatheroma (TCFA). The decrease of cap thickness increases 
the risk of rupture and release of thrombogenic material into the blood stream. The 
common occurrence of layered lesions created by cycles or rupture and healing 
indicates that ruptures infrequently lead to clinical manifestation and are an 
integral part of the plaque development process.  
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Calcification also appear during this process, typically at the interface between 
medial SMCs and atherosclerotic lesions [5].  The exact mechanism for vascular 
calcification is still unknown and subject of active research. Although calcifications 
have a thrombogenic effect when exposed to the blood stream, they may also have 
a stabilizing effect on the plaques. Calcifications are one of the hallmarks of disease 
progression, but they are not always present and are not necessary for the 
occurrence of cardiac events.  
 
 
Figure 2, Flow chart of the general concepts of the development of atherosclerosis. Reprinted from The 
American Journal of Medicine, 122/1, W. Insull, The Pathology of Atherosclerosis: Plaque Development and 
Plaque Responses to Medical Treatment, S3-S14, Copyright (2009), with permission from Elsevier 
 
Causes for the development of atherosclerotic disease described above are 
systemic, but certain locations are more likely to develop lesions . More specifically, 
studies of plaque rupture locations show that one of the critical locations is the 
upper section of the left anterior descending and left circumflex arteries, typically 
within 50 mm from the ostium [6]. Local hemodynamic properties, influencing 
shear stress on the endothelium as well as stress within the vessel wall have been 
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linked to lesion initiation, development and destabilization through a variety of 
processes [7]. 
1.3 Imaging	of	atherosclerosis	
Clinical manifestations of atherosclerosis only occur when blood circulation is 
restricted or blocked, in the cases of angina pectoris and myocardial infarction 
respectively [2]. In both cases, the distribution of iodinated contrast detected using 
fluoroscopy enables easy identification of the stenosed or blocked location and is 
generally sufficient to perform medical intervention.  
Unfortunately, fluoroscopy does not enable the identification of high-risk lesions. 
Lesions are extensively distributed throughout the vasculature but only few select 
locations present high-risk features (thin cap, superficial thrombosis, rupture).  
Additionally, these high-risk lesions are not necessarily associated with a higher 
degree of stenosis. Therefore, medical treatment of atherosclerotic disease is either 
reactive (stenting, thrombus removal following AMI) or based on lifestyle and lipid 
lowering drugs (statins).  
Atherosclerotic lesions are typically small (few mm3), and the locations of the 
coronary arteries, at the surface of the heart, lead to intense motion due to the 
myocardium contraction, making imaging of atherosclerosis using noninvasive 
methods very challenging. Among these efforts, quantification of calcification as a 
surrogate for disease risk assessment using CT has been performed with limited 
success  [5,8]. Although nuclear imaging is well suited to the study of metabolic 
disease and inflammation with an array of dedicated radiolabeled probes, the 
limited spatial resolution and long acquisition times has hindered adoption for 
imaging of coronary artery disease. MRI faces similar issues of motion artifacts 
and lack of spatial resolution. Although non-invasive imaging techniques present 
clear benefits, and advances in instrumentation performance are pushing the 
boundaries of temporal and spatial resolution, currently available instrumentation 
is still not suitable for the clinical evaluation of atherosclerosis.  
Given the many challenges in performing noninvasive imaging of coronary 
atherosclerosis, alternative catheter-based imaging techniques have been 
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developed over the last 25 years [9]. The first of these imaging modalities to have 
seen clinical adoption is intravascular ultrasound (IVUS). IVUS catheters consist 
of a small (<1 mm diameter) high frequency ultrasound transducer (20-60 MHz) 
mounted at the distal end of a rotating imaging coil (typically 30 rotations per 
second). IVUS enables the acquisition of cross-sectional images of the vessel. A 5-
10 mm penetration depth and ~100 µm axial and lateral resolution [9] enables 
assessment of vessel stenosis, and plaque burden, but limits the detection of small 
features such as the plaque thickness of TCFA. Additionally, lipid rich lesions are 
characterized by low signal reflection (hypoechoic region), whereas calcifications 
appear very distinctly (hyperechoic). Although this information is a clear step 
forward compared to fluoroscopy, spatial resolution as well as ability to determine 
plaque composition ultimately do not allow a thorough assessment of lesion 
characteristics [10]. Quantitative radiofrequency analysis of the backscattered 
signal showed promising results for the determination of lesion composition but 
has not been widely adopted in clinical practice [11]. Current advances in IVUS 
technology include the development of multiple frequency devices that aim at 
combining penetration depth enabled by lower frequency transducers (30-50 MHz) 
with the axial and lateral resolution of high frequency transducers (up to 120 
MHz) [12]. 
Optical Coherence Tomography (OCT) is a technique that can be considered an 
optical analog of IVUS, as it relies on near infrared (typically 1300 nm) 
backscattered light to generate contrast. In a similar fashion to IVUS, OCT enables 
depth-resolved measurement along the line of sight (A-line), and cross-sectional 
images (B-Scan) are obtained by rotation of the device’s optical core. A very active 
research field has led to steady improvements in OCT performance, driven by 
advances in light sources and detection scheme that leverage innovations in the 
telecommunication sector. Key features of current intravascular OCT systems are 
the high A-line rate (>25 kHz) that enables data acquisition at high speed (>100 
frames per second), and outstanding axial and lateral resolution (10-30µm). 
Unfortunately, this is achieved at the detriment of the penetration depth (1-2 mm), 
that does not enable the assessment of the overall plaque burden in advanced 
lesions. Additionally, the high scattering of red blood cells at 1300 nm requires 
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flushing of the blood from the artery segment during imaging. This is typically 
performed by a 10-20 cc bolus injection of iodinated contrast. 
The limitation of OCT and IVUS as standalone imaging techniques have led to the 
development of hybrid catheter imaging systems that aim to provide improved 
assessment of plaque characteristics. An obvious combination is IVUS and OCT, 
that combines the ability to assess overall plaque burden with the exquisite spatial 
resolution of OCT for the assessment of superficial lesion characteristics. Another 
direction for multimodal devices has been to combine a morphological imaging 
technique such as IVUS or OCT with an imaging modality able to provide 
compositional information. The section below will detail some of these approaches 
and their expected performances for the assessment of atherosclerotic lesions.  
 
 
Table 1. Multimodal intravascular imaging comparison.  (+++) indicates excellent performance of the 
modality; (++) moderate performance of the modality; (+) poor performance of the modality; (2) the modality 
is unable to provide this information; IVUS, intravascular ultrasound; RF-IVUS, radiofrequency analysis of 
the IVUS backscattered signal; OCT, optical coherence tomography; NIRS, near infrared spectroscopy; NIRF, 
near infrared fluorescence imaging; IVPA, intravascular photoacoustic imaging; FLIm, fluorescence life time 
imaging. Adapted from European Heart Journal, 122/1, C. Bourantas, Hybrid intravascular imaging: recent 
advances, technical considerations, and current applications in the study of plaque pathophysiology, Copyright 
(2016), with permission from Oxford University Press 
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Near infrared spectroscopy (NIRS) consists in measuring the absorption spectrum 
of the arterial wall in the near infrared. It is well known for the ability to 
characterize lipids and therefore was identified early as a promising approach to 
identify high risk lesions assumed to be characterized by a large lipid content. 
Intravascular implementation is performed using two side viewing fiber for light 
delivery and collection, axially offset such that most of the light propagates 
through the arterial wall before being collected. A NIRS-IVUS device has been 
clinically available since the mid-2000s [13] and the ability of the device to predict 
plaques likely to cause future events are currently being evaluated in clinical 
trials.  
A competing approach also aimed at detecting lipids in the lesions is intravascular 
photoacoustic (IVPA). Here, pulses of infrared light (typically 1720 nm) are sent to 
tissue, and absorption of the light leads to local thermal expansion that generate 
ultrasound waves detected with an ultrasound transducer. Because the presence 
of the transducer is required for IVPA, combination with IVUS is straightforward. 
IVPA provides depth resolved information, a clear advantage compared to NIRS 
where periadventitial adipose tissue may in some cases be mistaken for lipid rich 
atherosclerotic lesions. Nevertheless, successful implementation for in vivo use 
requires the development of suitable high frequency light sources and is currently 
the object of active work. Lipid specificity may benefit from the use of dual-
wavelength excitation to perform spectroscopic photoacoustic [12]. Safety issues 
with the delivery of high average power to tissue are significant and may also 
hinder clinical translation [14]   
Another promising approach to further the understanding of atherosclerosis 
processes is near infrared fluorescence (NIRF). It can detect biological processes 
with high specificity by combining molecular imaging probes, with dedicated 
imaging devices. This approach relies on near infrared excitation (typically 750 
nm), to take advantage of the higher penetration depth and reduced tissue 
autofluorescence generated by the excitation light. It has been implemented in 
combination with both OCT and IVUS. Combination with OCT is particularly 
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interesting as a single double clad fiber is used for both imaging modalities, 
enabling integration into devices with the same profile as standard clinical OCT 
catheters. Additionally, combination with OCT compares favorably with IVUS 
because both imaging modalities are inherently co-registered as they share the 
same light path [15]. Co-registration is a key feature as the fluorescence signal is 
dependent on the distance between the device and the vessel wall and must 
therefore be corrected to provide information about the probe concentration in 
tissue. Typical applications of NIRF-OCT are the detection of fibrin, a molecule 
associated with thrombus, to assess the risk of thrombus formation following stent 
implantation, or the detection of inflammation using a cysteine protease-
activatable NIRF imaging agent [16]. The reliance on molecular probes is creating 
regulatory challenges that limit the translation potential in human, as few 
molecular probes are currently cleared for use in human. 
Fluorescence lifetime imaging (FLIm) relies on excitation of endogenous 
fluorophores using pulsed UV light to provide tissue compositional information. 
This technique presents key features that make it a compelling choice to perform 
coronary artery disease lesion assessment when used in combination with a 
morphological imaging technique such as IVUS or OCT. The ability to perform 
time resolved measurement of fluorescence emission over a plurality of wavelength 
bands enables the identification of different fluorophores. Both lifetime and 
spectral information is ratiometric by nature and is therefore not directly impacted 
by changes in excitation/ collection geometry due to varying probe to vessel wall 
distance over the field of view. It is necessary to flush blood from the imaged area 
as blood absorption is high in the UV-visible range. This constraint is shared with 
OCT, routinely used in clinical practice. FLIm can be implemented in various 
ways, including full field or fiber-based point scanning techniques. The latter is 
most relevant for the implementation of FLIm as an intravascular imaging 
technique. Successful implementation relies on the development of high-speed 
data acquisition methods, and development of dedicated imaging catheters, 
described in section 2. 
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An alternative technique to fluorescence for the identification of tissue composition 
is Raman spectroscopy. This optical technique consists in the delivery of 
monochromatic light to a sample, and precise spectrally resolved measurement of 
the scattered light. The scattering phenomenon consist of Rayleigh scattering, also 
called elastic scattering, where photons change direction but maintain their 
energy, and therefore wavelength, and inelastic scattering, where photon energy 
is changing. Scattering leading to a decrease in energy, corresponding to an 
increase in wavelength, is called stokes Raman scattering, whereas in increase in 
energy, leading to a reduction of wavelength, is caused anti-stokes Raman 
scattering. The study of inelastic scattering component of light exiting the tissue 
provides information related to chemical bonds. Because different bonds lead to 
different levels of inelastic scattering, spectral properties of the inelastically 
scattered light provides information about chemical composition of samples. The 
information provided by Raman spectroscopy is typically much more specific than 
information provided by fluorescence, but implementation is challenging: only a 
small fraction of incoming photons undergoes inelastic scattering so signal levels 
are low, thus requiring extended acquisition time compared to fluorescence, and 
rejection of elastically scattered light is critical. Additionally, the collected signal 
also includes autofluorescence contribution, typically orders of magnitude higher 
than Raman contributions, as well as Raman background generated within the 
instrument, removed during post processing. Raman is widely implemented as a 
microscopy technique  [17] but fiber-based implementations are possible [18,19]. 
The fiber probe design needs to enable rejection of inelastically scattered light and 
Raman signal generated with the fiber itself, and maximize collection efficiency, 
and is thus consists of fiber bundles with integrated dielectric filters, limiting the 
possibilities of miniaturization. For the same reasons, implementation as a side 
viewing probe able to perform helical scanning is yet to be achieved. Although 
implementation of Raman spectroscopy into a device compatible with spectroscopic 
interrogation of the coronary vasculature is unlikely in the near future, the ability 
of Raman signal to provide label free, non-invasive detailed compositional 
information makes it a compelling tool for cardiovascular research applications. 
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1.4 Outline	of	thesis	
Successful implementation of FLIm for intravascular imaging relies on the 
development of dedicated instrumentation and data processing techniques. The 
second chapter of this work will focus on the different stages of the development of 
such instrumentation. This includes the implementation of a high speed FLIm 
data acquisition subsystem, the description of the integration of the FLIm 
subsystem with an IVUS clinical platform for combined morphological and 
compositional information, and the design, fabrication and testing of bimodal 
FLIm-IVUS catheters. Optical performances of intravascular FLIm catheters are 
limited using conventional distal end optics, so a novel freeform side viewing optic 
has been developed specifically for this application to address the shortcomings of 
the first multimodal FLIm-IVUS catheter design. The design and performances 
evaluation of this improved device are presented. Finally, a combined FLIm-
Raman integrated imaging system used for comparative imaging studies of 
coronary artery samples will be described. 
The instrumentation developed for this project enabled original imaging studies. 
In a third chapter, we will describe the evaluation of the FLIm-IVUS imaging 
system in vivo in animal model, followed by a study on diseased human coronary 
samples, aimed at furthering the understanding of sources of FLIm contrast. 
Results from comparative imaging of diseased human coronary samples using both 
FLIm and Raman spectroscopy will be presented. 
A summary of the key results and findings of this work will be presented in English 
and German in the fourth and fifth chapter, respectively.  
 
2. Optical instrumentation development 
 
2.1 Basics	on	fluorescence	and	time	resolved	fluorescence	
Fluorescence describes the effect where light is temporarily absorbed by a molecule 
and reemitted at a longer wavelength. More specifically, incoming electromagnetic 
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radiation energizes an orbital electron from the ground state to an excited singlet 
state. The relaxation to the ground state may lead to the emission of another 
photon. The path to the ground state may include non-radiative transitions 
(vibrational relaxation) such that the energy of the emitted photon is inferior to 
the energy of the absorbed photon, leading to a red-shifted emission called stokes 
shift. 
 
Fig. 3. Simplified Jablonski diagram that illustrates the transitions corresponding to the absorption and 
emission of photons observed during fluorescence processes.  
 
A fluorescent molecule can absorb and emit photons over specific wavelength 
ranges, determined by the available energy levels. This characteristic means that 
the fluorescence absorption and emission spectral properties may be used to 
identify fluorescence molecules. 
Additionally, the molecule remains in the excited state for a short duration before 
transitioning back to the ground state. This decay time varies between molecules 
and a measure of this property provides additional information that can be used in 
addition to spectral properties to discriminate different fluorophores.  
Biological fluorophores typically present wide overlapping emission spectra, so 
identification of species based on spectral properties alone is challenging (figure 
4). Adding lifetime provides therefore a useful additional dimension to generate 
tissue contrast. 
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Figure 4, Emission spectra of principal endogenous fluorophores encountered in autofluorescence studies. 
Reprinted from European Journal of Histochemistry, 58(4), Croce, A., & Bottiroli, G. Autofluorescence 
spectroscopy and imaging: a tool for biomedical research and diagnosis, Copyright (2014). CC 4.0  
 
2.2 Overview	of	possible	implementations	
Measurement of the wavelength properties is typically done by either dispersing 
the light using a prism or grating, or filtering the light using discrete filters, to 
measure the amount of emitted light at different wavelengths. As described in the 
previous section, this information can be complemented by the measurement of the 
fluorescence decay rate or lifetime. This phenomenon happens over a few 
nanoseconds, so dedicated fast instrumentation is required.  
The most common implementation, use routinely for microscopy applications, is 
time correlated single photon counting [20]. In this method, short (tens of 
picoseconds) light pulses are sent to the sample. Fluorescence light is collected and 
sent to a fast photodetector. Excitation pulse energy and instrument collection 
efficiency are set so that at most one fluorescence photon is detected for each 
excitation pulse. For each collected photon, the instrumentation can precisely 
determine the delay between the excitation pulse and the arrival of the 
fluorescence photon. By reproducing this process over hundreds to thousands of 
photons, it is possible to build a histogram of fluorescence photon arrival times, 
from which fluorescence decay properties can be derived. This method enables the 
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acquisition of high statistics data because there are few limits to how many 
photons can be collected from the sample. The main drawback is a slow acquisition 
speed, even with high repetition rate light sources. An alternative method is to use 
a gated detector, where the gate, synchronized with the excitation laser, is 
controlled by an adjustable delay mechanism such that different delay steps cover 
the whole decay time and enable recovery of the complete decay profile. 
With both methods, many excitation pulses are required to reconstruct the 
fluorescence decay of a single measurement point, a major disadvantage for 
imaging in intravascular setting where tissue is rapidly moving and where 
imaging acquisition needs to be performed while flushing blood from the imaging 
area.  
For this work, we have used a time resolved fluorescence measurement technique 
that enables acquisition of fluorescence decays over multiple spectral bands from 
a single excitation photon. This technique, refined over more than 10 years of 
development at UC Davis and other research institutions, will be described in the 
following section [21,22].  
2.3 High	speed	FLIm	instrumentation	
The approach used here is described as a pulse sampling technique [23]. It is 
conceptually simple: the fluorescence emission, generated by a high energy 
excitation pulse (~µJ/pulse), is sampled by a high-speed digitizer. It is fast because 
each target location can be characterized by a single excitation pulse. This scheme 
relies on the availability of fast, high gain photodetectors such as microchannel 
plate photomultipliers (MCP-PMT) and high bandwidth and high sampling rate 
electronic, and the quality of the data is limited by the ability to collect a high 
number of fluorescence photons from each excitation pulse.  
Earlier implementations of pulse sampling time resolved fluorescence relied on 
Nitrogen lasers, able to generate 337 nm pulses of sub-nanosecond duration (~700 
ps), and high energy (up to 100 µJ), albeit at lower repetition rate (30 Hz 
typical) [24]. Because of the high pulse energy, the optical throughput of the 
excitation and collection paths of the instrument are not critical. This type of laser 
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is well suited for point measurements, where the ability to perform single 
wavelength measurements in less than a second is sufficient. When combined with 
a scanning spectrometer or filter wheel to perform wavelength resolved 
measurements, the scanning speed of the spectrometer (mechanical rotation of the 
grating) or rotation of the filter wheel is a limitation so a laser repetition rate of 
tens of Hertz is again sufficient.  
Time resolved fluorescence images are created by the combination of many 
individual point measurements, at least hundreds of points, and typically 
thousands, depending on the size of the area of interest and the required spatial 
sampling. Laser repetition rate becomes therefore a key factor for a practical 
implementation of fluorescence lifetime imaging. Imaging of ex vivo samples can 
be performed over several minutes because the main limitations to a prolonged 
data acquisition sequence are drying of samples and limited throughput when 
imaging many samples. As discussed in previous sections, optical imaging in 
intravascular setting requires to displace blood from the field of view by means of 
a flushing agent. This is especially true for fluorescence when using UV excitation, 
because of the high extinction coefficient of blood in the UV region (~485 cm-1 at 
355 nm) [25].  Bolus injection of flushing agents are well accepted in clinical 
practice  [26] but limit the duration of an imaging sequence to a few seconds. To 
enable the acquisition of fluorescence lifetime images in such short time frame, we 
adopted 355 nm pulsed UV fiber laser (80 ps pulses, Fianium, UK) with a repetition 
rate of 20 KHz.  
As described earlier, the ability to perform time resolved fluorescence 
measurements over different wavelength bands is key to enable differentiation of 
various fluorophores. This is achieved here by splitting the fluorescence signal in 
four bands using a combination of dichroic mirrors and bandpass filters. This 
compares advantageously to scanning monochromators or motorized filter as this 
arrangement does not require moving parts and all spectral bands can be acquired 
simultaneously. Because pulse sampling methods relies on costly high-speed 
detectors and sampling electronics, simply duplicating the detection channels for 
each wavelength range of interest is not practical. Instead, the system includes 
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varying lengths of delay fiber that perform temporal multiplexing, such that the 
fluorescence light from different spectral bands reaches the photodetector delayed 
in time. The incremental length of the delay fibers is determined to generate 
sufficient delay (45 ns) to prevent overlap between signals of different spectral 
bands. 
The photodetector used for this instrument is a multialkali photocathode MCP-
PMT (R3809U-50, Hamamatsu, Japan). This device presents a short rise time (160 
ps), a low transit time spread (25 ps), and a photocathode area suitable for the 
coupling of light delivered by the four delay fibers (11 mm diameter). The PMT is 
coupled to a 40 dB gain, high bandwidth (3GHz) amplifier (AM-1607-3000, MITEQ, 
NY) and the resulting signal is then sampled by a high-speed digitizer (12.5 GS/s, 
3 GHz, 8-bit, 512 Mbytes, PXIe-5185, National Instruments, Austin, TX). 
 
 
Figure 5: Schematic of multispectral time resolved fluorescence lifetime measurement instrumentation. A 
single photodetector and high-speed digitizer are used for the acquisition of time resolved fluorescence in four 
different spectral bands from a single excitation pulse, using a temporal multiplexing scheme implemented 
with varying lengths of delay fibers.  
 
2.4 FLIm‐IVUS	instrumentation	requirements	for	in	vivo	use	[P1]	
The FLIm acquisition system above relies on a single multimode fiber for delivery 
of the excitation light as well as collection of the fluorescence signal generated by 
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the tissue. This implementation is much easier to integrate into miniature imaging 
probes than the fiber bundles using separate fibers for the excitation and collection 
paths that are typically used for such measurements. This enabled the fabrication 
of a low profile FLIm-IVUS imaging device reported previously [27]. 
Unfortunately, this previous system relied on separate FLIm and IVUS imaging 
cores, integrated in a dual lumen device that performed sequential scanning of the 
sample. This approach is well suited to imaging of ex vivo samples [28] but not to 
acquire co-registered FLIm and IVUS data in presence of motion, a key 
requirement in an imaging system developed for in vivo use.  
A suitable fully integrated FLIm-IVUS catheter system requires: 
 An integrated imaging catheter where both imaging modalities are 
packaged into a single imaging core.  
 An integrated motor drive unit (MDU) to perform imaging core rotation and 
ultrasound radiofrequency as well as optics rotary coupling 
 An integrated data acquisition system 
 
The different elements of the system will be described in the following sections.   
2.5 Integrated	FLIm	IVUS	imaging	catheter	
Coronary arteries are characterized by an inner diameter of 3-5 mm at the ostium 
(branching location from ascending aorta) that reduces further as they branch out. 
Intravascular imaging devices for the imaging of atherosclerosis are not required 
to be able to image each artery segment. The distribution of critical lesions is 
following patterns and is highest in the upper sections of the left anterior 
descending artery (LAD), right coronary artery (RCA), and circumflex artery (see 
figure 6). In these locations, the inner diameter of healthy arteries is ~3 mm, but 
stenosis due to development of atherosclerotic lesions leads to a reduction in vessel 
lumen sizes, that dictates a typical imaging section diameter of ~1 mm (see table 
2).  
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Figure 6. Anatomical terminology of coronary vasculature. Coronary.pdf: Patrick J. Lynch, medical 
illustrator derivative work [1]: Fred the Oyster (talk) adaption and further labeling: Mikael Häggström - 
Coronary.pdf, CC BY-SA 3.0 
Other common features are a working length of ~135 cm to access the coronary 
arteries via femoral access, and an integrated pullback system that enables the 
combined translation and rotation of the imaging core within the device’s sheath 
to perform helical scanning without displacement of the sheath with respect to the 
vessel. 
 
Name	(Manufacturer)	 Modality	 Crossing	
profile	(F)	
Frame	 rate	
(fps)	
Pullback	
speed	(mm/s)	
Dragonfly C7(Abbott) OCT 2.7 100 25  
OptiCross (Boston Scientific) IVUS 3.1 30 1  
Revolution (Philips) IVUS 3.2 30 1 
TVC-MC9 (InfraredX) IVUS+NIRS 3.2 16 0.5 
FLIm‐IVUS	(UC	Davis)	 IVUS+FLIm	 3.6	 30	 4‐10	mm/s	
Table 2. Characteristics of some clinical intravascular devices currently available for imaging of coronary 
arteries, and custom FLIm-IVUS catheter. Intravascular devices cross section dimensions are typically 
expressed in French (F), a measure of distance defined as one third of a millimeter.  
Finally, the devices must be able to function in presence of sharp bends (bending 
radius < 15 mm), commonly encountered at the coronary ostium and within the 
coronary artery tree. 
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The integrated FLIm-IVUS catheter designed for this project [P1] was derived 
from a clinical IVUS catheter (Boston Scientific OptiCross). The imaging core, 
described in figure 7 is composed of custom distal-end housing and torque coil, and 
a hub that provides a mechanical connection for rotation as well as an electrical 
and optical interface. The ultrasound channel consists of a 40 MHz ultrasound 
transducer located in the distal section of the housing. The optical channel consists 
of a 200 µm core high-OH fused silica fluorine doped multimode fiber, terminated 
with an aluminum coated prism. Both channels are disposed in a tandem 
configuration, with reduced axial offset (450 µm from the center of the transducer 
to the center of the prism). To further improve coregistration, the ultrasound beam 
is tilted by 4º backward, whereas the prism is integrated with fiber to provide a 10-
degree forward tilt of the optical beam, to achieve an overlap of the beam at a 
distance of ~1 mm. The tilt of the ultrasound transducer presents the additional 
benefit of limiting back-reflection artifacts from the device’s sheath. 
Manufacturing of the probe is a delicate, multi-step process. The ultrasound is first 
bonded into the housing and wired using a thin coaxial cable (46 Ga). Electrical 
connections between wire core and gold anode of the transducer, and wire shield 
and conductive backing of the transducer (cathode) are performed with conductive 
silver epoxy. The pre-assembled fiber optic and prism are then aligned and bonded 
into the housing. Both fiber and coaxial cable are inserted into the torque coil, 
bonded to the distal housing with cyanoacrylate adhesive. The proximal end of the 
torque coil is then bonded to the hub. The coaxial cable is connected to a small 
high-frequency filtering printed circuit assembly located inside of the hub that 
integrates the electrical pins visible in figure 7.  The proximal end of the fiber optic 
is routed through an opening inside of the printed circuit assembly and inserted 
and bonded into the ferrule and polished in place. The distal end housing and 
torque coil are custom elements fabricated to accommodate the two imaging 
channels, leading to an increase of the imaging core diameter (FLIm-IVUS: 830 
µm, Boston Scientific OptiCross: 570 µm). 
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Figure 7. Details of the FLIm-IVUS catheter imaging core. Top view: complete imaging core with details of 
electrical and optical interfaces integrated in the hub. Bottom view: close-up of the imaging core distal end 
illustrating the integration of ultrasound and optical channels. 
The sheath, described in figure 8, is composed of a shaft and telescope. The 
telescope is directly derived from the OptiCross IVUS catheter whereas the shaft 
has been adapted to fulfill the requirement of the FLIm-IVUS device. It presents 
a larger inner diameter (1.02 mm) required to accommodate the increased 
dimensions of the imaging core, and the shaft imaging section consists of a custom 
polymethylpentene extrusion (MX004, Mitsui Chemicals) that presents both low 
ultrasound impedance (~1.8 Mrayls) and suitable optical properties (high 
transparency, low autofluorescence).  
 
Figure 8:  Details of the FLIm-IVUS imaging sheath. The imaging section has a section of 3.7 Fr and enables 
a 50 mm pullback. 
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2.6 Integrated	FLIm‐IVUS	motor	drive	unit	
The motor drive unit provides rotation and pullback motions and integrates a 
rotary interface for the ultrasound radiofrequency signal as well as the optical 
channel. It is derived from a clinical Boston Scientific motor drive, extensively 
modified to accommodate an optical channel. The modifications, visible in figure 9, 
consist in a modification of the catheter shaft to include a spring-loaded 
intermediate fiber optic stub for reliable connection with the optical channel of the 
catheter hub (label 1). The fiber stub extends to the end-face coupled rotary joint 
located in the handle of the MDU (label 2), for transmission of the optical signal to 
the WSM via a fiber optic patch cord (label 3). The motor and gearbox that drives 
the rotation of the shaft was offset with a gear train to enable the positioning of 
the rotary joint in line with the shaft (label 4). Finally, the pullback motor was 
modified to achieve increased pullback speeds required for FLIm imaging (label 5). 
Despite these modifications, the FLIm-IVUS MDU keeps similar dimensions as 
the original MDU and is compatible with all accessories of the Boston Scientific 
MDU (pullback sled, sterile bag). 
 
 
Figure 9: MDU modifications. Left: original motor drive unit (MDU). Right: modified MDU. Parts modified to 
integrate an optical channel with rotary joint are highlighted in red.   
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2.7 Integrated	FLIm	and	IVUS	data	acquisition		
The FLIm-IVUS system is closely derived from the clinical IVUS system (iLab) and 
leverages the clinical user interface to provide real time display of IVUS images: it 
is therefore possible to use IVUS images guide the positioning of the FLIm-IVUS 
catheter to an area of interest, before proceeding with a bimodal acquisition 
sequence. A drawback of the clinical console is that no external synchronization is 
available, and therefore the IVUS data obtained from the clinical console cannot 
be co-registered with FLIm data. To address this key requirement, the iLab 
acquisition unit was modified to provide an analogical IVUS signal output, 
connected to a dedicated digitizer synchronized with the FLIm digitizer (see figure 
10). During bi-modal scans, IVUS and FLIm signal are synchronized to less than 
a microsecond. The combination of spatial registration of FLIm and IVUS data, 
enabled by the overlapping imaging beams, and precise synchronization of the data 
acquisition of both modalities enables the acquisition of a perfectly co-registered 
multimodal dataset. 
 
Figure 10: Description of the data acquisition scheme that enables the acquisition of co-registered FLIm and 
IVUS data using a combination of overlapping imaging beams and synchronized data acquisition.  
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The frame rate of the IVUS system is determined by the rotation speed of the 
imaging core of 30 turns per second. The FLIm-IVUS acquisition sequence was 
fixed at 5 s, a duration compatible with blood clearing using a bolus injection. It 
consists therefore of 150 ultrasound B-scans (cross sectional images). Each B-scan 
is composed of 256 ultrasound depth resolved measurements (A-scans). The FLIm 
subsystem sends UV excitation pulses at a frequency of 20 kHz, thus leading to 
100 000 measurements in the same 5 s period. Data processing was performed 
using a 4-fold average to increase signal to noise ratio, leading to 25 000 
independent FLIm measurements. This corresponds to 167 measurements per 
catheter rotation. 
2.8 FLIm	and	IVUS	data	processing	
A typical approach for extracting fluorescence decay parameters consists of using 
multi-exponential techniques [29]. Exponential functions match the relaxation 
dynamics of fluorescence systems, but because the formulation is non-linear with 
respect to decay parameters, least square evaluation of coefficients requires 
computationally intensive iterative optimization. Here, FLIm data was processed 
using a constrained least square Laguerre basis expansion technique [30]. 
Weighted Laguerre polynomials form an orthogonal basis of function that have 
applications in dynamic systems modeling [31]. When performing least square 
deconvolution with Laguerre expansion, fluorescence decays are expressed as a 
linear combination of Laguerre basis functions and thus estimation of expansion 
coefficients is comparatively simpler than multiexponential methods. A drawback 
of the Laguerre approach is that the basis functions present oscillations, so 
estimations of the fluorescence decay in the presence of noise may lead to non-
physical solutions (non-necessarily monotone decreasing). This is addressed by the 
adoption of additional constraints, namely that the resulting fluorescence 
estimation is positive, decaying and convex, thus limiting the results to physically 
realistic functions  [32]. Using this method, for each pullback, fluorescence lifetime 
and intensity were derived for each of the four channels of the instrument and 25 
000 measurement locations.   
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IVUS images are reconstructed by first extracting the envelope of the RF signal, 
with log compression, to obtain the A-line scans.  256 A-line scans were then 
combined into a cross sectional image (B-scan). The processed IVUS data obtained 
from one pull-back consists of approximately 150 frames.  
Bimodal FLIm-IVUS images are reconstructed by registering each FLIm-derived 
parameter to the right frame and angular position based on time stamp 
information available for both IVUS and FLIm data. 3D surface rendering was 
obtained using a segmentation of the IVUS data to recover the geometry of the 
vessel lumen. 
The feasibility of acquiring multimodal data with this FLIm-IVUS system and data 
processing method was demonstrated in vivo in swine model and applied to 
imaging studies of ex vivo human coronary artery samples (Chapter 3). 
 
2.9 High	performance	free‐form	optics	for	iv‐	FLIm	imaging	[P2]	
During testing of the FLIm-IVUS catheter described in the previous sections, the 
presence of non-uniform rotational distortion (NURD) was apparent (Figure 11). 
NURD is an imaging artifact caused by variations of the rotation speed of the distal 
end of the device, in turn leading to non-uniform angular sampling. It is a common 
occurrence in intravascular imaging devices if the torsional stiffness of the imaging 
core (provided by the torque coil) is low or the frictions between imaging core and 
sheath are high, leading to a stick and release cyclical oscillation of the imaging 
core.  
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Figure 11: illustration of non-uniform rotational distribution (NURD). Asymmetric friction leads to a non-
uniform rotation that leads to uneven angular sampling. Repeat measurements at similar angles are visible 
in the sector highlighted in red.   
 
The friction between the core and sheath is influenced by the bending radius of the 
catheter, the torsional stiffness of the torque coil and the bending stiffness of the 
imaging core. The bending radius is dependent on the path of the catheter, itself 
constrained by anatomical characteristics of the aorta and coronary vessels. The 
design of the torque coil consists of two counter-wound layers optimized to provide 
high torsional stiffness and low bending stiffness so only minimal improvements 
can be expected by refining the torque coil design. The main NURD contributor 
identified in the FLIm-IVUS catheter design is the bending stiffness of the 
multimode fiber. The dimensions of the core (200 µm) were chosen to maximize 
signal collection efficiency but lead to a much higher bending stiffness than typical 
single mode fibers used for intravascular OCT, for example. The bending stiffness 
of a fiber is proportional to its area moment of inertia: 
𝐼௫ ൌ 𝜋. 𝑑
ସ
64  
 
Eq. 1 
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The multimode fiber used here, with a 220 µm cladding diameter, presents 
therefore an ~860% increase in bending stiffness compared to a 125 µm cladding 
diameter single mode fiber. 
Reducing the multimode fiber diameter would address the NURD issue, at the 
expense of collection efficiency, proportional to the square of the fiber diameter. 
The reduction of fiber cross section could be compensated by the adoption of a distal 
end focusing optics to increase collection efficiency, but the miniature optics 
currently used for intravascular optical devices such as OCT – gradient index 
(GRIN) lens or fused ball lens designs - are not suitable for intravascular FLIm 
(Figure 12).  
 
 
Figure 12: Illustration of side-viewing intravascular imaging probes distal end optics used in combination with 
a 100 µm core fiber. Top: 0.2 NA lithium doped GRIN lens. The low NA of the lens leads to a >5 mm element, 
not suitable for use in a high flexibility catheter. Bottom: ball lens. Beam expansion requires the splicing of 
dissimilar fiber diameters. Use of the ball lens in liquids requires the addition of a short length of tubing to 
cap the lens. This increases bulk, complexity and introduces astigmatism. 
 
GRIN based side viewing optics for intravascular application typically rely on 
silver doped GRIN element, available with numerical apertures (NA) of up to 0.5. 
In that case, the optics typically consist of the fiber, assembled with a glass rod 
where the optical beam is expending, followed by a short length of GRIN optic used 
as a micro-lens to focus the light at a sufficient working distance, and a prism to 
reflect the light in a radial direction [33]. Unfortunately, silver doped GRIN 
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elements present strong absorption and autofluorescence at 355 nm and cannot be 
used for our application [34]. An alternative dopant, lithium, presents optical 
properties suitable for use with UV light, at the cost of a reduced NA (~0.2). 
Focusing the light from a 0.22 NA multimode fiber means that some of the light 
coupled to the fiber’s highest modes cannot be guided by the optic. But more 
importantly, the limited NA leads to a much longer element for an identical pitch 
(Length of 0.25 pitch lens: 3.05mm (0.2 NA) vs. 1.15 mm (0.5 NA)). The optical 
assembly that provides a working distance of ~1.5mm, typical for intravascular 
devices, would have a length of more than 5 mm (see figure 12). Reducing the rigid 
length of the imaging core is a key factor to enable navigation in tortuous anatomy 
such as the coronary vasculature, so this UV compatible GRIN optics is not 
suitable. 
A second approach is to use a polished fused ball lens to provide reflection via total 
internal reflection of the polished face and focusing by the spherical surface of the 
ball. Such fibers are manufactured routinely for OCT applications by splicing a 
short length of no core fiber at the end of the single mode fiber, and fusing the 
distal end of no core fiber into a sphere, polished at an angle in a final step [33]. 
For use in combination with multimode fibers, it is necessary that the no core fiber 
diameter is larger than the multimode fiber to allow for unconstrained beam 
expansion. Splicing of dissimilar fiber sizes is in itself a challenging process. The 
design optimization is also heavily constrained as selection of the probe’s working 
distance is determined by the ability to form a sphere of the right curvature. 
Finally, a FLIm-IVUS application requires the imaging core to be submerged in 
liquids. Because the design relies on index mismatch for total internal reflection 
as well as focusing, it is necessary to enclose the optic into a glass capillary, further 
increasing bulk and complexity. 
A novel design or side viewing fiber optic was developed to address these 
limitations [P2]. It consists of a short length of pure fused silica, terminated with 
a curved, reflective coated surface that performs radial redirection of the beam as 
well as focusing (Figure 13). When using a broadband reflective coating, the design 
is suitable for UV-Visible-IR operation with negligible chromatic aberrations as 
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light only travels in pure silica and reflection off the curved surface is not 
dependent on wavelength. It is suitable for operation in air as well as immersed in 
liquid without any additional steps and enables correction of astigmatism 
introduced by a catheter sheath. Further description of the manufacturing process 
and evaluation of optical performance is described in [P2] 
 
 
Figure 13: Schematic of freeform reflective micro-optics (top). Computer representation of micro-optic 
integrated in the distal housing of an improved FLIm-IVUS imaging core (bottom left). Close up of a fabricated 
imaging core (bottom right). The torque coil is carried over from the previous generation of imaging core and 
could be replaced with a reduced dimensions coil to bring the dimensions of the imaging section to ~3.1 Fr. 
 
2.10 FLIm‐Raman	imaging	as	a	validation	tool	
Raman spectroscopy relies on precise measurement of inelastically scattered light 
(Stokes and anti-Stokes scattering) from samples. Because inelastic scattering is 
determined by vibrational states of molecular bonds, the presence of specific bonds 
can be identified from the spectral shift observed in the collected light. Raman 
spectroscopy can be implemented using a variety of source wavelength; therefore, 
spectral shifts are typically expressed in wavenumber, a quantity independent 
from the excitation wavelength, according to Eq. 2: 
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Eq.2 
Raman instrumentation is conceptually simple, as it consists of a monochromatic 
light source, combined with a filter used for rejection of elastically scattered light 
and a wavelength dispersion mechanism. In practice, accurate measurements 
necessitate a narrow emission light source with stable center frequency, and 
effective blocking of the excitation light using steep dielectric filters. High signal 
to noise ratio/ high spectral resolution measurements are achieved by using high 
quality dispersion elements such as transmission gratings, combined with low 
noise photodetectors, typically cooled charge coupled devices (CCD).  
Raman is a point measurement technique often used in analytical chemistry to 
identify compounds or characterize and monitor processes. For heterogeneous 
samples, additional information is provided by mapping the spectroscopic 
signature for a series or locations. This approach is very valuable for the study of 
biological systems, typically at the microscopic level leading to interrogated 
volumes of a few cubic micrometers.  For mapping of larger samples, the use of 
lower lateral resolution fiber optic probes scanned over the sample are an 
alternative to tiling of microscopy images, and lead to faster data acquisition for a 
given area at the cost of a reduced lateral resolution.  
These fiber optic probes typically consist of bifurcated probes with a fiber for 
delivery of excitation light, multiple fibers for signal collection, and may include 
distal end optics to improve signal collection and lateral resolution. Filters are 
integrated at the distal end of the probe, in direct correspondence to the excitation 
and collection fibers, to block Raman signal generated in the delivery fiber, and 
block excitation light propagation into the collection fibers, respectively.  
This arrangement is amenable to multimodal imaging, because it is 
straightforward to replace one of the collection fibers with a fiber dedicated to an 
additional optical modality, with minimal impact on Raman signal collection 
performance. Such fiber optic probe is used for the integration of FLIm with Raman 
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spectroscopy as reported in [P3]. It is derived from a probe previously 
reported  [18], and used for combined FLIm-Raman imaging of an ex vivo human 
sample [35]. This trifurcated probe consists of a central FLIm excitation/ collection 
fiber without any filter element (first leg of the probe), connected to the FLIm 
instrumentation described in section 2.3. One of the peripheral fibers, in 
combination with a low pass filter, is connected to the Raman light source (second 
leg of the probe). 7 peripheral fibers, in combination with a long pass filter, are 
used for Raman collection and connected to the spectrometer (third leg). The last 
peripheral fiber, unfiltered, can be used for bifurcated fluorescence imaging and is 
typically not used. 
The probe can be used as a point measurement device or mounted on a raster 
scanning stage to generate bimodal spectroscopic images. Among the advantages 
of the combination of these two spectroscopic images, we can list the ability to 
quickly scan large areas by leveraging the high point measurement speed (100-
1000 points/second), to identify areas where higher specificity measurements 
enabled by Raman spectroscopy, can be directed. Another potential use is 
performing comparative imaging, where samples are being imaged using both 
FLIm and Raman techniques, such that relationships between information 
provided by each modalities can be systematically investigated. This is the subject 
of [P3]. 
 
3. Towards in vivo characterization of atherosclerotic lesions  
The FLIm-IVUS catheter system presented above is designed to be suitable for 
imaging of coronary arteries. The physical characteristics of this bimodal catheter 
are close to other comparable intravascular imaging devices and the 5 s imaging 
sequence is compatible with blood clearing using a bolus injection of flushing 
solution. The ability of the FLIm-IVUS system to acquire co registered images in 
realistic conditions was evaluated in swine. The system was then used to perform 
imaging studies on ex vivo human samples to further investigate how FLIm 
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information can supplement morphological information from IVUS to better 
characterize atherosclerotic lesions [P1]. 
3.1 In	vivo	validation	of	intravascular	FLIm‐IVUS	
A key factor to optimize in vivo data acquisition is the determination of flushing 
parameters. In clinical practice, flushing for OCT imaging is performed using 
iodinated contrast. Iodinated contrast is transparent in the visible-IR range, 
presents adequate viscosity and osmolarity properties, and is already in use in 
catheterization procedures because it is the standard-of-care contrast agent for 
angiography. Unfortunately, we observed strong absorption at wavelengths below 
400 nm (Figure 14).  
 
Figure 14: Transmission spectra of 1mm thick samples of iodinated contrast (Visipaque 320, corresponding to 
652 mg/mL Iodixanol) and 10% Dextran40 solution. Both solutions present outstanding transparency in the 
visible region (>400 nm) but strong absorption of iodinated contrast in the near UV prevent its use for FLIm 
imaging. 
Dextran solution used in some clinical settings as an alternative flushing agent 
presents excellent transparency and suitable viscosity and osmolarity properties 
(Table 2). Two different Dextran solutions were tested: a combination with sodium 
chloride alone, and a combination of dextrose and sodium chloride. Better stability 
of the electrocardiogram was observed for the Dextran/ dextrose/ NaCl solution. 
This is consistent with other publications evaluating different flushing agents [36]; 
this solution was therefore chosen for our experiments. 
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  Blood  Visipaque  320 
(Iodinated 
contrast) 
0.9%  NaCl 
(saline) 
10%  Dextran  40, 
0.9% NaCl 
10% Dextran 40, 5% 
dextrose,  0.14% 
NaCl 
Transmission  at  355 
nm (1mm path) 
NA  35%  98%  >97%  >97% 
Viscosity (cP)  3‐4  11.8  0.69  ~4  ~4 
Osmolarity 
(mOsmol/kg water) 
280‐300  290  308  310  310 
Comments    Preferred  OCT 
flushing 
solution 
 Requires  high 
flow  (>10 
mL/s) 
 T‐wave drop 
 Hypotension 
 Good  flushing 
performances 
 T‐wave drop 
 Hypotension 
 Good  flushing 
performances 
 No  noticeable  EKG 
changes 
Table 2: Characteristics of different flushing agents used for optical coronary artery imaging. 
 
Tests were performed using an automated injection system (Medrad Advanta, 
Warrendale, PA) to provide more consistency and flexibility in determining 
injection rates and duration. A 7Fr guide was inserted in the left main coronary 
stem. The FLIm-IVUS device was inserted in the mid LAD. Repeat 20 mm bimodal 
imaging pullbacks were performed. Displacement of blood could be tracked using 
IVUS because speckles due to blood scattering subside when the flushing solution 
reaches the imaging plane of the device, typically 3 s after the start of the injection. 
The injection was maintained for another 5 s, corresponding to the end of the 
pullback sequence. We observed that injection rates of 3 mL/s or more were 
necessary to perform efficient flushing. No clear improvement was observed by 
increasing the flushing rate past 4 mL/s. It can be noted that the quality of the 
flush is strongly dependent on the proper insertion of the guide catheter into the 
left stem. High flushing flows (>5 mL/s) have led to occasional unseating of the 
guide catheter from the artery ostium and is not recommended.  
These imaging tests were performed in healthy swine (~75 kg, ~5 months) that 
presented healthy vessels. No contrast was therefore expected in the FLIm images, 
and the ability to acquire robust data in vivo was assessed by the mean and 
standard deviations of the recovered lifetime for various fluorescence signal 
intensities (Figure 15).  
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Figure 15: En-face FLIm images of healthy arteries. Fluorescence intensity (a) and lifetime (b) en face images 
were segmented to remove the guide wire. Lifetime values and standard deviation in function of signal 
intensity, for repeat acquisitions at the same location (c) and averaged over 5 different locations (d). Minimal 
variations of lifetime values across the field of view, despite large variations in intensity, demonstrate that 
FLIm data can be collected in conditions representative of clinical use. Adapted from [P1] CC 4.0 
 
An illustration of the ability of FLIm to detect features based on fluorescence 
lifetime and spectral information was demonstrated by imaging a stent with 
fluorescence targets deployed in the LAD [P2]. 
3.2 Imaging	study	of	ex	vivo	human	coronary	samples	using	a	FLIm‐
IVUS	catheter	
Intravascular imaging devices are invasive devices that present significant risks 
and therefore regulatory requirements for testing in human subjects are stringent. 
Additionally, studies in human subject are complex because unlike imaging studies 
in oncology, for example, no samples are available for further analysis to confirm 
findings from imaging, and clinical validations typically consist of outcome studies, 
where the location of culprit lesions in future acute coronary events is compared 
with earlier imaging data.  
For these reasons, a first important step consists in the evaluation of intravascular 
imaging devices on ex vivo human samples. As outlined in section 1.2, the entire 
adult population is affected by some level of atherosclerosis, so most ex vivo 
coronary specimens are likely to present lesions that can be used for an initial 
assessment of the ability of the device to identify optical signature relevant to 
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plaque pathophysiological characteristics. For this study, samples were obtained 
from the University of Pennsylvania heart transplant program in compliance with 
the University of Pennsylvania and University of California, Davis institutional 
review boards, either from heart transplant patients or organ donors.  
 Coronary artery segments were harvested from hearts, chilled in isopentane, 
frozen in liquid nitrogen and sent to our laboratory. Before imaging, samples were 
thawed, mounted in custom holders and immersed in a 37 ºC phosphate buffered 
saline bath. A circulation system was used to flush the artery during imaging to 
prevent vessel collapse. After imaging, the artery and holder were submerged in 
formalin solution; the solution was circulated inside of the sample to maintain 
lumen shape during the fixation process and facilitate future co-registration. 
 
 
Figure 16. Workflow of sample preparation and imaging. Fluid circulation in artery lumen during imaging 
and fixation prevents lumen collapse and improves registration accuracy. Proximal and distal suturing of 
sample on holder limit axial shrinking during fixation. 
 
FLIm-IVUS data was processed using the method described in section 2.8. 
Histology sections were first coarsely registered with imaging frames based on 
axial location and angular alignment from sample inking.  
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Figure 17: FLIm-histology comparison. Fibrous tissue and fibrous caps can be distinguished by increased 
lifetimes at 390 and 450 nm. Diffuse intimal thickening has shorter lifetimes than all other components in all 
wavelength ranges. Foam cell infiltration causes increased lifetimes at both 450 nm and 540 nm, as does 
necrosis. The dashed line indicates the location of the FLIm-IVUS cross-section and CD68 image. This region 
includes a fibrous cap infiltrated with foam cells (purple arrowheads), fibrous cap (green arrowhead), and a 
thin fibrous cap overlying necrotic core (red arrowhead). The penetration depth of FLIm is ~150 um, thus we 
FLIm does not see the deeper necrotic calcified core, but it is visible with IVUS (blue asterisk). Scale bar = 1 
mm. 
 
Fine registration was performed by identifying landmarks in IVUS and histology. 
The presence of eccentric lumen, branches, and calcifications provides a variety of 
landmarks that facilitates the histology registration process. FLIm information is 
Towards in vivo characterization of atherosclerotic lesions| 38 
 
withheld during the fine registration step to prevent biasing of the results that 
could arise from providing both histology and FLIm during the registration 
process.  
Systematic assessment of FLIm signature in comparison with various histological 
features on 30+ artery samples is still ongoing, but early results have shown some 
clear associations between FLIm parameters and presence of early stage plaque 
(390 nm channel), and mFC infiltration (540 nm channel).  
 
 
3.3 FLIm‐	Raman	spectroscopy	comparative	imaging	study	[P3]	
Sources of FLIm contrast are not easily identified based on histological findings 
alone. mFC infiltration could be easily linked with increase in 540 nm lifetime but 
the source of 390 nm lifetime could not be univocally associated with any specific 
histological finding. 390 nm FLIm contrast is clearly linked with plaque 
boundaries, but not all plaques present the same increase in 390 nm lifetime. 
Measurement of pure compounds to allow for identification of possible species 
responsible for the observed lifetime increase presents limitations. For a start, 
several species (collagen, elastin, some lipids) present a peak fluorescence emission 
at shorter wavelengths [37]. Additionally, fluorescence decay properties of 
molecules are modulated by their microenvironment, such that measurement of 
pure compounds may not accurately reflect their emission properties in tissue [38]. 
Here, we decided to leverage the ability of Raman spectroscopy to provide a 
detailed signature of tissue composition to identify possible sources of FLIm 
contrast. More specifically, Raman spectral features, corresponding to the presence 
of specific molecular bonds, are routinely used to identify molecular species with 
high specificity [39].  
For this work, the combined FLIm/Raman instrumentation described in 2.10 was 
used to image human coronary artery samples. Raman data acquisition is 
inherently slower than fluorescence due to the lower efficiency of the Raman 
process. For this study, extended exposure times (10s) for each location were used 
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to maximize signal SNR. The speed limitation made imaging of the whole sample 
surface with Raman impractical, therefore imaging was performed sequentially. 
At first, the entire surface was scanned with FLIm (~1-2 min depending on sample 
size). Select regions of interest were then defined to include transition regions 
between low lifetime regions (healthy) and increased lifetime regions to perform 
Raman data acquisition. When possible, regions presenting lifetime increase in 
only one channel were selected, to facilitate the identification of compounds related 
to lifetime increases in a single FLIm spectral band. 
Raman data was processed (wavenumber calibration, baseline correction, 
normalization) to obtain spectra for each location. The comparison with FLIm data 
was performed via a multivariate linear regression approach, to identify which 
Raman feature is most related to variations in fluorescence lifetime. A first 
approach would be to develop a linear model that predicts FLIm values based on 
Raman spectra. Directly using the Raman intensities as independent variables of 
the regression presents issues. Indeed, when an independent variable is highly 
correlated with a combination of one or more other independent variables, the 
contribution of that independent variable is influenced by other independent 
variables. This multicollinearity issue leads to unreliable estimations of the 
regression coefficients. This is clearly the case with Raman spectra, where 
neighboring wavenumbers are highly correlated. An option is to perform a PCA 
and use the loadings as independent variables. This addresses the 
multicollinearity issue but regression coefficients become hard to interpret as they 
present features for multiple wavenumbers at once. An alternative is to consider 
the FLIm parameters as the independent variables, and use a linear regression 
model to predict Raman intensities, followed by a computation of the coefficient of 
determination for each wavenumber to see if significant amount of the Raman data 
variance can be explained by the FLIm model. 
The main finding of the study was that lower wavelength (<400 nm) FLIm contrast 
was linked with LDL accumulation, characterized by Raman as a combination of 
cholesterol and β-Carotene  [40,41]. This finding is interesting because it suggests 
that conclusions from previous imaging studies that associated lifetime contrast in 
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that wavelength band with varying amounts of collagen based on histological 
finding, needs revisiting [28,42].  
Imaging validation studies on the basis of comparative imaging present challenges, 
due for example to the difference in penetration depths or the need to create hybrid 
instrumentation with possible degradations of the performances of each single 
imaging modality. Nevertheless, imaging based validations also present strong 
benefits. Indeed, a critical bottleneck of histology based validation of imaging 
techniques is the need for extensive human intervention for sample processing 
(grossing, fixation, sectioning, staining), histology interpretation (extraction of 
relevant histological features), and registration with imaging data. Here, the 
availability of a co-registered imaging dataset means that after definition of the 
data processing methods, minimal human intervention is required. It becomes 
therefore possible to greatly increase the number of samples of a study with 
minimal additional workload beyond the initial data acquisition step.  
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4. Summary 
Cardiovascular diseases are one of the leading causes of deaths and atherosclerosis 
is the main culprit. This condition is characterized by the build-up of plaque in the 
arteries throughout the life of individuals that creates narrowing that can impede 
blood flow, but also cause heart attacks or strokes when these plaques release 
thrombogenic material in the bloodstream.  Because of its clinical relevance, 
medical research of atherosclerosis is a very active field. Decades of research efforts 
have led to improved understanding of the disease mechanisms, but a full 
understanding of atherosclerosis pathophysiology is still elusive. Imaging of 
lesions with non-invasive modalities is challenging, because a suitable modality 
would require high spatial resolution to image millimeter sized lesions, high 
temporal resolution to deal with large motion of the beating heart, and molecular 
sensitivity to provide information regarding the physiological processes at play. 
Therefore, most observations in human are originating from artery studies that 
provide a snapshot of lesions but do not enable to follow the development over time. 
Animal models have been developed to facilitate research on atherosclerosis, but 
replicating the decades-long lesion development process in time scales suitable for 
medical research is challenging. Alternatively, in vitro studies based on cellular 
models of atherosclerosis have been developed, but fail to capture some of the 
effects thought to be critical for lesion development, such as hemodynamics.  
An imaging device able to fully characterize lesions in vivo in patient and enable 
repeat snapshots that capture lesion development would be a great asset for 
researchers and clinicians alike. Unfortunately, no such instrument is currently 
available. In the pursuit of the perfect intravascular imaging device, imaging 
research is split between improvements in imaging techniques currently available 
in clinical settings such as intravascular ultrasound (IVUS), or intravascular 
optical coherence tomography, and development of catheter-based 
implementations of a variety of biomedical imaging techniques, such as 
fluorescence, photoacoustic, Raman spectroscopy, or near-infrared spectroscopy.  
Fluorescence lifetime imaging (FLIm), widely used as a label free microscopy 
imaging technique, provides a biochemical signature of tissue based on 
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autofluorescence properties. Here, we developed an integrated FLIm-IVUS 
imaging catheter system, derived from a clinical IVUS system, suitable for the 
interrogation of coronary arteries in vivo. This system maintains the benefits of 
the clinical system, such as real time IVUS image display, useful for selections of 
areas of interest, and a form factor suitable for use in clinical setting. In addition, 
it is able to perform acquisitions of co-registered FLIm and IVUS data at high 
speed. High FLIm data acquisition speeds of up to 20000 fluorescence decay 
measurements over four different spectral channels are performed in five seconds. 
This speed is made possible by a pulse sampling acquisition scheme with temporal 
multiplexing of the different spectral bands, developed by our group. Dedicated low 
profile (3.7 Fr), flexible, FLIm-IVUS catheters were designed, fabricated and 
tested. The motor drive unit from the clinical system was redesigned to integrate 
an optical channel without adversely affecting IVUS performance [P1].  
The ability of this instrument to acquire robust FLIm data in vivo was evaluated 
in swine model. Data acquisition procedure parameters (flushing fluid, flow rate) 
were optimized to demonstrate that the FLIm-IVUS system proposed here is 
suitable for data acquisition in conditions representative of percutaneous 
interventions in human patients. 
Imaging of ex vivo human samples using the catheter system confirmed the benefit 
of a bimodal system. IVUS capability provides accurate morphological information 
that facilitates accurate registration with histology sections for FLIm imaging 
validation. We could also demonstrate that based on FLIm contrast, locations of 
macrophage foam cells accumulations could be identified from the 540 nm 
instrument channel. Strong contrast was also observed in the 390 nm spectral 
band of the instrument. This contrast may be related to the presence of 
extracellular lipids and could provide additional information about early stages of 
lesion development.  
Further optimization of optical and mechanical performance of the catheter was 
achieved with the development of a monolithic freeform reflective optics. This novel 
type of side viewing optic was developed to address limitations of currently 
available side viewing optics (gradient index or angled polished ball lenses) that 
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make them unsuitable for intravascular FLIm. The freeform optics demonstrates 
improved optical performances in compact, fluorescence background free, 
monolithic element, and is suitable for use in liquids without the need of an 
additional cap.  In comparison to the first version of the bimodal instrument that 
relies on a 200 µm core fiber for FLIm excitation delivery and signal collection, the 
adoption of the distal end optic enables the use of a 100 µm core fiber optic with 
minimal degradation of collection efficiency. This new implementation presents 
increased flexibility (16x reduction in fiber bending stiffness) and enables 
improvements lateral resolution [P2]. 
Finally, a pilot comparative imaging study of ex vivo human artery samples was 
performed combining the pulse sampling FLIm data acquisition technique with 
Raman spectroscopy, by means of a bimodal forward-viewing optical probe. 
Methods based on multiple regression techniques were developed for the 
automated analysis of FLIm contrast sources using Raman spectroscopy data. 
Results from this pilot study confirmed the link between fluorescence emission 
above 500 nm and presence of superficial macrophage foam cells, whereas increase 
in lifetime below 400 nm was associated with the presence of carotenoids and low 
density lipoproteins. The approach described here is well suited to the study of a 
large number of samples as, unlike traditional imaging validation based on 
histology, this comparative imaging approach does not require human intervention 
for sample processing, section registration and extraction of histological features 
[P3].  
Development of dedicated intravascular instrumentation combined with further 
understanding of the information provided by FLIm by means of histological 
studies as well as comparative imaging will improve the relevance of FLIm as a 
practical tool for the investigation of atherosclerosis. Future work will focus on 
regulatory activities to enable studies in human subject, where the ability of FLIm 
to provide the biochemical signature of lesions in vivo may be leveraged to improve 
understanding of the disease natural history, develop new drugs, and possibly be 
used in clinical settings to improve patient treatment. 
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5. Zusammenfassung 
Herz-Kreislauf-Erkrankungen sind eine der häufigsten Todesursachen, und 
Arteriosklerose ist der Hauptverursacher. Dieser Zustand ist durch die 
Ansammlung von Plaques in den Arterien verursacht, welche sich im Laufe des 
Lebens bei einer Parson ansammeln können. Diese Plaques können eine 
Verengung hervorruft, welche den Blutfluss behindern, aber auch Herzinfarkte 
oder Schlaganfälle verursachen kann, wenn dieses thrombogenes Material in den 
Blutkreislauf abgeben. Aufgrund ihrer klinischen Relevanz ist die medizinische 
Erforschung der Atherosklerose hoch aktuell. Zwar haben jahrzehntelange 
Forschungsanstrengungen zu einem besseren Verständnis der 
Krankheitsmechanismen geführt, ein lückenloses Verständnis der 
Pathophysiologie der Atherosklerose, ist jedoch noch nicht gegeben. Zum Beispiel 
ist die Abbildung von Läsionen mit nicht-invasiven Modalitäten bis heute eine 
Herausforderung, da die geeignete Modalität nicht nur eine hohe räumliche 
Auflösung zur Abbildung von Läsionen in Millimetergröße und eine hohe zeitliche 
Auflösung zur Bewältigung großer Bewegungen des schlagenden Herzens 
ermöglichen muss, sondern auch eine molekulare Empfindlichkeit erfordert, um 
Informationen über physiologische Prozesse zu bestimmen. Durch diese 
komplexen Anforderungen stellen die meisten durchgeführten 
Arterienuntersuchungen beim Menschen, eine Momentaufnahme der Läsionen da, 
und bieten jedoch keine Möglichkeit, die Entwicklung zeitlich zu verfolgen. Es 
wurden Tiermodelle entwickelt, um die Erforschung von Arteriosklerose zu 
erleichtern, aber die Nachbildung des jahrzehntelangen Entwicklungsprozesses 
von Läsionen in für die medizinische Forschung geeigneten Zeiträumen bleibt eine 
Herausforderung. Alternativ wurden in-vitro Studien entwickelt, die auf 
zellulären Atherosklerose-Modellen basieren, jedoch einige der Effekte, die für die 
Entwicklung von Läsionen als kritisch angesehen werden, wie z. B. die 
Hämodynamik, nicht erfassen. 
 
Ein bildgebendes Gerät, das in der Lage ist, Läsionen in vivo bei Patienten 
vollständig zu charakterisieren und wiederholte Schnappschüsse zu ermöglichen, 
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die die Entwicklung von Läsionen erfassen, wäre für Forscher und Kliniker 
gleichermaßen von großem Nutzen. Leider ist derzeit kein solches Instrument 
verfügbar. Bei der Suche nach dem perfekten Gerät für die intravaskuläre 
Bildgebung wird die bildgebende Forschung aufgeteilt in Verbesserungen der 
Bildgebungstechniken, die derzeit in klinischen Umgebungen wie der 
intravaskulären Ultraschalltomographie (IVUS) oder der intravaskulären 
optischen Kohärenztomographie verfügbar sind, und in die Entwicklung 
katheterbasierter Implementierungen einer Vielzahl biomedizinischer 
Bildgebungsverfahren wie Fluoreszenz, Photoakustik, Raman-Spektroskopie oder 
Nahinfrarot-Spektroskopie. 
 
Die Fluoreszenzlebensdauer-Bildgebung (FLIm), die häufig als markierungsfreie 
mikroskopische Bildgebungstechnik verwendet wird, liefert eine biochemische 
Signatur von Gewebe auf der Grundlage der Autofluoreszenzeigenschaften. Im 
Rahmen der Promotion wurde ein integriertes FLIm-IVUS-
Bildgebungskathetersystem entwickelt, das von einem klinischen IVUS-System 
abgeleitet wurde und für die Abfrage von Koronararterien in vivo geeignet ist. 
Dieses System behält die Vorteile des klinischen Systems, wie die Echtzeit-IVUS-
Bilddarstellung bei, die für die Auswahl von Bereichen von Interesse nützlich ist 
und einen Formfaktor, der für die Verwendung in der klinischen Umgebung 
geeignet ist. Darüber hinaus können mit ihm gemeinsam registrierte FLIm- und 
IVUS-Daten mit hoher Geschwindigkeit erfasst werden. Hohe FLIm-
Datenerfassungsgeschwindigkeiten von bis zu 20000 
Fluoreszenzabklingmessungen über vier verschiedene Spektralkanäle können in 
fünf Sekunden durchgeführt werden. Diese Geschwindigkeit wird durch ein von 
unserer Gruppe entwickeltes Impulsabtastungserfassungsschema mit zeitlichem 
Multiplexen der verschiedenen Spektralbänder ermöglicht. Im Rahmen der Arbeit 
wurden spezielle flexible FLIm-IVUS-Katheter mit einem kleinen Durchmesser 
(3,7 Fr) entworfen, hergestellt und getestet. Weiterhin wurde die 
Motorantriebseinheit aus dem klinischen System so umgestaltet, dass sie einen 
optischen Kanal integriert, ohne die IVUS-Bildgebung nachteilig zu beeinflussen 
[P1]. 
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Die Fähigkeit dieses Instruments, robuste FLIm-Daten in vivo zu erfassen, wurde 
im Schweinemodell demonstriert. Die Parameter des Datenerfassungsverfahrens 
(Spülflüssigkeit, Durchflussrate) wurden optimiert, um zu zeigen, dass das hier 
vorgeschlagene FLIm-IVUS-System für die Datenerfassung unter Bedingungen 
geeignet ist, die für perkutane Eingriffe bei menschlichen Patienten repräsentativ 
sind. 
 
Die Abbildung von ex-vivo Humanproben unter Verwendung des Kathetersystems 
bestätigte den Nutzen eines bimodalen Systems. Die IVUS-Funktion bietet genaue 
morphologische Informationen, die eine präzise Registrierung mit histologischen 
Schnitten für die FLIm-Bildgebungsvalidierung ermöglichen. Wir konnten auch 
zeigen, dass auf der Grundlage des FLIm-Kontrasts Positionen von Makrophagen-
Schaumzell-Ansammlungen aus dem Instrumentenkanal von 540 nm identifiziert 
werden konnten. Ein starker Kontrast wurde auch im 390-nm-Spektralbereich 
beobachtet. Dieser Kontrast kann mit dem Vorhandensein extrazellulärer Lipide 
zusammenhängen und zusätzliche Informationen über frühe Stadien der 
Läsionsentwicklung liefern. 
 
Eine weitere Optimierung der optischen und mechanischen Leistung des 
Katheters wurde mit der Entwicklung einer monolithischen Freiform-
Reflexionsoptik erreicht. Diese neuartige Seitenblickoptik wurde entwickelt, um 
Einschränkungen der derzeit verfügbaren Seitenblickoptik (Gradientenindex oder 
abgewinkelte polierte Kugellinsen), die sie für intravaskuläres FLIm ungeeignet 
machen, zu beseitigen. Die Freiformoptik zeigt verbesserte optische Eigenschaften 
bei kompakten, fluoreszenzhintergrundfreien, monolithischen Elementen und 
eignet sich zur Verwendung in Flüssigkeiten, ohne dass eine zusätzliche Kappe 
erforderlich ist. Im Vergleich zur ersten Version des bimodalen Instruments, das 
für die FLIm-Anregung und die Signalerfassung auf einer 200-µm-Kernfaser 
beruht, ermöglicht die Verwendung der distalen Endoptik die Verwendung einer 
100-µm-Kernfaser mit minimaler Verschlechterung der Detektionseffizienz. Diese 
neue Implementierung bietet eine erhöhte Flexibilität (16-fache Reduzierung der 
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Faserbiegesteifigkeit) und ermöglicht gleichzeitig eine Verbesserung der lateralen 
Auflösung [P2]. 
 
Schließlich wurde eine Pilotstudie zur vergleichenden Bildgebung von ex-vivo-
Proben menschlicher Arterien durchgeführt, bei der die FLIm-Datenerfassungs 
mit der Raman-Spektroskopie mittels einer bimodalen optischen 
Vorwärtssichtsonde kombiniert wurde. Für die automatisierte Analyse von Daten 
aus der FLIm und Raman-Spektroskopie wurden Methoden basierend auf 
multiplen Regressionstechniken entwickelt. Die Ergebnisse dieser Pilotstudie 
bestätigten den Zusammenhang zwischen der Fluoreszenzemission über 500 nm 
und dem Vorhandensein oberflächlicher Makrophagenschaumzellen, wohingegen 
die Erhöhung der Lebensdauer unter 400 nm mit dem Vorhandensein 
hervorgehobener Lebensdauerverlängerungen bei Carotinoiden und 
Lipoproteinen niedriger Dichte (LDL) verbunden war. Der hier beschriebene 
Ansatz eignet sich gut für die Untersuchung einer großen Anzahl von Proben, da 
im Gegensatz zur herkömmlichen Bildgebungsvalidierung auf der Grundlage der 
Histologie für diesen Ansatz der vergleichenden Bildgebung keine Eingriffe des 
Menschen zur Probenverarbeitung, Schnittregistrierung und Extraktion von 
histologischen Merkmalen erforderlich sind [P3]. 
 
Die Entwicklung dedizierter intravaskulärer Instrumente in Kombination mit 
einem besseren Verständnis der von FLIm bereitgestellten Informationen mittels 
histologischer Studien, sowie einer vergleichenden Bildgebung, wird die Relevanz 
von FLIm als praktisches Instrument für die Untersuchung von Arteriosklerose 
erhöhen. Zukünftige Arbeiten werden sich auf regulatorische Aktivitäten 
konzentrieren, um Studien direkt am Menschen zu ermöglichen. Dies wird es 
ermöglichen das Potential von FLIm, d.h. die markerfreie Erfassung von 
biochemische Signatur von Läsionen in vivo, besser zu nutzten und so ein besseres 
Verständnis über den Krankheitsverlaufs und neue Therapiemöglichkeiten für die 
Versorgung von Patienten zu gewährleisten. 
 
Bibliography| 48 
 
Bibliography 
1.  "CDC, NCHS. Underlying Cause of Death 1999-2013 on CDC WONDER 
Online Database, released 2015," (2015). 
2.   W. Insull Jr., "The Pathology of Atherosclerosis: Plaque Development and 
Plaque Responses to Medical Treatment," Am. J. Med. 122, S3–S14 (2009). 
3.   H. C. Stary, A. B. Chandler, S. Glagov, J. R. Guyton, W. Insull, M. E. 
Rosenfeld, S. A. Schaffer, C. J. Schwartz, W. D. Wagner, and R. W. Wissler, 
"A definition of initial, fatty streak, and intermediate lesions of 
atherosclerosis. A report from the Committee on Vascular Lesions of the 
Council on Arteriosclerosis, American Heart Association.," Circulation 89, 
2462–2478 (1994). 
4.   Flood Christofer, Gustafsson Maria, Pitas Robert E., Arnaboldi Lorenzo, 
Walzem Rosemary L., and Borén Jan, "Molecular Mechanism for Changes in 
Proteoglycan Binding on Compositional Changes of the Core and the Surface 
of Low-Density Lipoprotein–Containing Human Apolipoprotein B100," 
Arterioscler. Thromb. Vasc. Biol. 24, 564–570 (2004). 
5.   T. M. Doherty, K. Asotra, L. A. Fitzpatrick, J.-H. Qiao, D. J. Wilkin, R. C. 
Detrano, C. R. Dunstan, P. K. Shah, and T. B. Rajavashisth, "Calcification in 
atherosclerosis: bone biology and chronic inflammation at the arterial 
crossroads," Proc. Natl. Acad. Sci. U. S. A. 100, 11201–11206 (2003). 
6.   M.-K. Hong, G. S. Mintz, C. W. Lee, B.-K. Lee, T.-H. Yang, Y.-H. Kim, J.-M. 
Song, K.-H. Han, D.-H. Kang, S.-S. Cheong, J.-K. Song, J.-J. Kim, S.-W. Park, 
and S.-J. Park, "The Site of Plaque Rupture in Native Coronary Arteries: A 
Three-Vessel Intravascular Ultrasound Analysis," J. Am. Coll. Cardiol. 46, 
261–265 (2005). 
7.   B. R. Kwak, M. Bäck, M.-L. Bochaton-Piallat, G. Caligiuri, M. J. A. P. 
Daemen, P. F. Davies, I. E. Hoefer, P. Holvoet, H. Jo, R. Krams, S. Lehoux, C. 
Monaco, S. Steffens, R. Virmani, C. Weber, J. J. Wentzel, and P. C. Evans, 
"Biomechanical factors in atherosclerosis: mechanisms and clinical 
implications†," Eur. Heart J. 35, 3013–3020 (2014). 
8.   J. M. Tarkin, M. R. Dweck, N. R. Evans, R. A. P. Takx, A. J. Brown, A. 
Tawakol, Z. A. Fayad, and J. H. F. Rudd, "Imaging Atherosclerosis," Circ. Res. 
118, 750 (2016). 
9.   M. E. Brezinski, G. J. Tearney, N. J. Weissman, S. A. Boppart, B. E. Bouma, 
M. R. Hee, A. E. Weyman, E. A. Swanson, J. F. Southern, and J. G. Fujimoto, 
"Assessing atherosclerotic plaque morphology: comparison of optical 
coherence tomography and high frequency intravascular ultrasound.," Heart 
77, 397 (1997). 
10.   T. Ma, B. Zhou, T. K. Hsiai, and K. K. Shung, "A Review of Intravascular 
Ultrasound–Based Multimodal Intravascular Imaging: The Synergistic 
Approach to Characterizing Vulnerable Plaques," Ultrason. Imaging (2015). 
11.   S. Brugaletta, H. M. Garcia-Garcia, P. W. Serruys, A. Maehara, V. Farooq, G. 
S. Mintz, B. de Bruyne, S. P. Marso, S. Verheye, D. Dudek, C. W. Hamm, N. 
Farhat, F. Schiele, J. McPherson, A. Lerman, P. R. Moreno, B. Wennerblom, 
M. Fahy, B. Templin, M.-A. Morel, G. A. van Es, and G. W. Stone, 
"Relationship Between Palpography and Virtual Histology in Patients With 
Acute Coronary Syndromes," Intracoronary Imaging PROSPECT Study 5, 
S19–S27 (2012). 
Bibliography| 49 
 
 
12.   T. Ma, M. Yu, J. Li, C. E. Munding, Z. Chen, C. Fei, K. K. Shung, and Q. Zhou, 
"Multi-frequency intravascular ultrasound (IVUS) imaging," IEEE Trans. 
Ultrason. Ferroelectr. Freq. Control 62, 97–107 (2015). 
13.   R. D. Madder, M. Husaini, A. T. Davis, S. Van Oosterhout, J. Harnek, M. 
Götberg, and D. Erlinge, "Detection by near-infrared spectroscopy of large 
lipid cores at culprit sites in patients with non-st-segment elevation 
myocardial infarction and unstable angina," Catheter. Cardiovasc. Interv. 86, 
1014–1021 (2015). 
14.   M. Wu, A. Fw van der Steen, E. Regar, and G. van Soest, "Emerging 
Technology Update Intravascular Photoacoustic Imaging of Vulnerable 
Atherosclerotic Plaque," Interv. Cardiol. Lond. Engl. 11, 120–123 (2016). 
15.   H. Yoo, J. W. Kim, M. Shishkov, E. Namati, T. Morse, R. Shubochkin, J. R. 
McCarthy, V. Ntziachristos, B. E. Bouma, F. A. Jaffer, and G. J. Tearney, 
"Intra-arterial catheter for simultaneous microstructural and molecular 
imaging in vivo," Nat Med 17, 1680–1684 (2011). 
16.   Jaffer Farouc A., Vinegoni Claudio, John Michael C., Aikawa Elena, Gold 
Herman K., Finn Aloke V., Ntziachristos Vasilis, Libby Peter, and Weissleder 
Ralph, "Real-Time Catheter Molecular Sensing of Inflammation in 
Proteolytically Active Atherosclerosis," Circulation 118, 1802–1809 (2008). 
17.   Keisaku Hamada, Katsumasa Fujita, Nicholas Isaac Smith, Minoru 
Kobayashi, Yasushi Inouye, and Satoshi Kawata, "Raman microscopy for 
dynamic molecular imaging of living cells," J. Biomed. Opt. 13, 1–4 (2008). 
18.   S. Dochow, D. Ma, I. Latka, T. Bocklitz, B. Hartl, J. Bec, H. Fatakdawala, E. 
Marple, K. Urmey, S. Wachsmann-Hogiu, M. Schmitt, L. Marcu, and J. Popp, 
"Combined fiber probe for fluorescence lifetime and Raman spectroscopy," 
Anal. Bioanal. Chem. 407, 8291–8301 (2015). 
19.   M. Jermyn, K. Mok, J. Mercier, J. Desroches, J. Pichette, K. Saint-Arnaud, L. 
Bernstein, M.-C. Guiot, K. Petrecca, and F. Leblond, "Intraoperative brain 
cancer detection with Raman spectroscopy in humans," Sci. Transl. Med. 7, 
274ra19 (2015). 
20.   W. Becker, A. Bergmann, and C. Biskup, "Multispectral fluorescence lifetime 
imaging by TCSPC," Microsc. Res. Tech. 70, 403–409 (2007). 
21.   Y. Sun, R. Liu, D. S. Elson, C. W. Hollars, J. A. Jo, J. Park, Y. Sun, and L. 
Marcu, "Simultaneous time- and wavelength-resolved fluorescence 
spectroscopy for near real-time tissue diagnosis," Opt. Lett. 33, 630–632 
(2008). 
22.   D. R. Yankelevich, D. Ma, J. Liu, Y. Sun, Y. Sun, J. Bec, D. S. Elson, and L. 
Marcu, "Design and evaluation of a device for fast multispectral time-resolved 
fluorescence spectroscopy and imaging," Rev. Sci. Instrum. 85, (2014). 
23.   R. Cubeddu, D. Comelli, C. D’Andrea, P. Taroni, and G. Valentini, "Time-
resolved fluorescence imaging in biology and medicine," J. Phys. Appl. Phys. 
35, R61–R76 (2002). 
24.   Q. Fang, T. Papaioannou, J. A. Jo, R. Vaitha, K. Shastry, and L. Marcu, 
"Time-domain laser-induced fluorescence spectroscopy apparatus for clinical 
diagnostics," Rev. Sci. Instrum. 75, 151–162 (2004). 
25.  "Optical Absorption of Hemoglobin," 
http://omlc.ogi.edu/spectra/hemoglobin/index.html. 
Bibliography| 50 
 
26.   Y. Ozaki, H. Kitabata, H. Tsujioka, S. Hosokawa, M. Kashiwagi, K. Ishibashi, 
K. Komukai, T. Tanimoto, Y. Ino, S. Takarada, T. Kubo, K. Kimura, A. 
Tanaka, K. Hirata, M. Mizukoshi, T. Imanishi, and T. Akasaka, "Comparison 
of Contrast Media and Low-Molecular-Weight Dextran for Frequency-Domain 
Optical Coherence Tomography," Circ. J. 76, 922–927 (2012). 
27.   D. Ma, J. Bec, D. R. Yankelevich, D. Gorpas, H. Fatakdawala, and L. Marcu, 
"Rotational multispectral fluorescence lifetime imaging and intravascular 
ultrasound: bimodal system for intravascular applications," J. Biomed. Opt. 
19, 066004–066004 (2014). 
28.   H. Fatakdawala, D. Gorpas, J. W. Bishop, J. Bec, D. Ma, J. A. Southard, K. 
B. Margulies, and L. Marcu, "Fluorescence Lifetime Imaging Combined with 
Conventional Intravascular Ultrasound for Enhanced Assessment of 
Atherosclerotic Plaques: an Ex Vivo Study in Human Coronary Arteries," J 
Cardiovasc. Transl. Res. (2015). 
29.   J. R. Lakowicz, Principles of Fluorescence Spectroscopy (Third edition. New 
York : Kluwer Academic/Plenum, [2006] ©2006, 2006). 
30.   J.-M. I. Maarek, L. Marcu, W. J. Snyder, and W. S. Grundfest, "Time-resolved 
Fluorescence Spectra of Arterial Fluorescent Compounds: Reconstruction 
with the Laguerre Expansion Technique," Photochem. Photobiol. 71, 178–187 
(2000). 
31.   P. Van den Hof, B. Wahlberg, P. Heuberger, B. Ninness, J. Bokor, and T. 
Oliveira e Silva, "Modelling and Identification with Rational Orthogonal Basis 
Functions," 12th IFAC Symp. Syst. Identif. SYSID 2000 St. Barbara CA USA 
21-23 June 2000 33, 445–455 (2000). 
32.   J. Liu, Y. Sun, J. Qi, and L. Marcu, "A novel method for fast and robust 
estimation of fluorescence decay dynamics using constrained least-squares 
deconvolution with Laguerre expansion," Phys. Med. Biol. 57, 843 (2012). 
33.   M. J. Gora, M. J. Suter, G. J. Tearney, and X. Li, "Endoscopic optical 
coherence tomography: technologies and clinical applications [Invited]," 
Biomed. Opt. Express 8, 2405–2444 (2017). 
34.  "GRINTECH GmbH Gradient Index Optics," 
https://www.grintech.de/en/gradient-index-optics/. 
35.   S. Dochow, H. Fatakdawala, J. E. Phipps, D. Ma, T. Bocklitz, M. Schmitt, J. 
W. Bishop, K. B. Margulies, L. Marcu, and J. Popp, "Comparing Raman and 
fluorescence lifetime spectroscopy from human atherosclerotic lesions using a 
bimodal probe," J. Biophotonics 9, 958–966 (2016). 
36.   M. J. Suter, M. Kashiwagi, K. A. Gallagher, S. K. Nadkarni, N. Asanani, A. 
Tanaka, G. B. Conditt, A. Tellez, K. Milewski, G. L. Kaluza, J. F. Granada, B. 
E. Bouma, and G. J. Tearney, "Optimizing flushing parameters in 
intracoronary optical coherence tomography: an in vivo swine study," Int. J. 
Cardiovasc. Imaging 31, 1097–1106 (2015). 
37.   A. C. Croce and G. Bottiroli, "Autofluorescence spectroscopy and imaging: a 
tool for biomedical research and diagnosis.," Eur. J. Histochem. EJH 58, 2461 
(2014). 
38.   S. Draxler and M. E. Lippitsch, "Lifetime-Based Sensing:  Influence of the 
Microenvironment," Anal. Chem. 68, 753–757 (1996). 
39.   I. ur. Rehman, Zanyar. Movasaghi, and Shazza. Rehman, "Vibrational 
spectroscopy for tissue analysis," 
http://www.crcnetbase.com/isbn/9781439836088. 
| 51 
 
 
40.   A. Lattermann, C. Matthäus, N. Bergner, C. Beleites, B. F. Romeike, C. 
Krafft, B. R. Brehm, and J. Popp, "Characterization of atherosclerotic plaque 
depositions by Raman and FTIR imaging," J. Biophotonics 6, 110–121 (2013). 
41.   C. Stiebing, L. Schmölz, M. Wallert, C. Matthäus, S. Lorkowski, and J. Popp, 
"Raman imaging of macrophages incubated with triglyceride-enriched oxLDL 
visualizes translocation of lipids between endocytic vesicles and lipid 
droplets," J. Lipid Res. 58, 876–883 (2017). 
42.   J. Park, P. Pande, S. Shrestha, F. Clubb, B. E. Applegate, and J. A. Jo, 
"Biochemical characterization of atherosclerotic plaques by endogenous 
multispectral fluorescence lifetime imaging microscopy," Atherosclerosis 220, 
394–401 (2012). 
 
  
| 52 
 
  
Publications| 53 
 
 
Publications 
 
[P1]	 In	vivo	label‐free	structural	and	biochemical	imaging	of	coronary	
arteries	using	an	integrated	ultrasound	and	multispectral	fluorescence	
lifetime	catheter	system	(2017)	
 
 Reprinted from [1.  J. Bec, J. E. Phipps, D. Gorpas, D. Ma, H. Fatakdawala, K. B. 
Margulies, J. A. Southard, and L. Marcu, 2017. In vivo label-free structural and 
biochemical imaging of coronary arteries using an integrated ultrasound and 
multispectral fluorescence lifetime catheter system, Nature Scientific Reports, 7, 
8960] in accordance with the Creative Commons license CC BY 4.0 
Erklärungen zu den Eigenanteilen des Promovenden sowie der weiteren 
Doktoranden/Doktorandinnen als Koautoren an der Publikation. 
1J. Bec, 2J. E. Phipps, 3D. Gorpas, 4D. Ma, 5H. Fatakdawala, 6K. B. Margulies, 
7J. A. Southard, and 8L. Marcu, "In vivo label-free structural and biochemical 
imaging of coronary arteries using an integrated ultrasound and multispectral 
fluorescence lifetime catheter system," Scientific Reports 7, 8960 (2017). 
Beteiligt an (Zutreffendes ankreuzen) 
 1 2 3 4 5 6 7 8 
Konzeption des Forschungsansatzes X       X 
Planung der Untersuchungen X      X X 
Datenerhebung X X   X  X  
Datenanalyse und Interpretation X X X X  X   
Schreiben des Manuskripts X X      X 
Vorschlag Anrechnung 
Publikationsäquivalent 
1.0        
 
 
Publications| 54 
 
Publications| 55 
 
 
Publications| 56 
 
Publications| 57 
 
 
Publications| 58 
 
Publications| 59 
 
 
Publications| 60 
 
Publications| 61 
 
 
Publications| 62 
 
 
 
 
 
Publications| 63 
 
 
 
[P2]	 Broadband,	 freeform	 focusing	 micro‐optics	 for	 side‐viewing	
imaging	catheter	(2019)	
 
Reprinted with permission from [Julien Bec, Cai Li, and Laura Marcu, 
"Broadband, freeform focusing micro-optics for a side-viewing imaging catheter," 
Opt. Lett. 44, 4961-4964 (2019)] © The Optical Society 
Erklärungen zu den Eigenanteilen des Promovenden sowie der weiteren 
Doktoranden/Doktorandinnen als Koautoren an der Publikation. 
1J. Bec, 2C. Li, and 3L. Marcu, "In vivo label-free structural and biochemical 
imaging of coronary arteries using an integrated ultrasound and multispectral 
fluorescence lifetime catheter system," Scientific Reports 7, 8960 (2017). 
Beteiligt an (Zutreffendes ankreuzen) 
 1 2 3 
Konzeption des Forschungsansatzes X  X 
Planung der Untersuchungen X   
Datenerhebung X X  
Datenanalyse und Interpretation X X  
Schreiben des Manuskripts X  X 
Vorschlag Anrechnung 
Publikationsäquivalent 
1.0   
 
Publications| 64 
 
Publications| 65 
 
 
Publications| 66 
 
Publications| 67 
 
 
 
 	
Publications| 68 
 
 	
Publications| 69 
 
 
	
[P3]	 Investigating	 origins	 of	 FLIm	 contrast	 in	 atherosclerotic	 lesions	
using	combined	FLIm‐Raman	Spectroscopy	(2019)	
 
 
Submitted to Frontiers in Cardiovascular Medicine [Julien Bec, Tanveer Ahmed 
Shaik, Christoph Krafft, Thomas W. Bocklitz, Alba Alfonso-Garcia, Kenneth B. 
Margulies, Jürgen Popp, Laura Marcu, "Investigating origins of FLIm contrast in 
atherosclerotic lesions using combined FLIm-Raman Spectroscopy,"]  
Erklärungen zu den Eigenanteilen des Promovenden sowie der weiteren 
Doktoranden/Doktorandinnen als Koautoren an der Publikation. 
1J. Bec, 2T. A. Shaik, 3C. Krafft, 4T. W. Bocklitz, 5A. Alfonso-Garcia, 6 J. Popp, 
7Kenneth B. Margulies, and 8L. Marcu, " Investigating origins of FLIm contrast 
in atherosclerotic lesions using combined FLIm-Raman Spectroscopy,"  
 Beteiligt an (Zutreffendes ankreuzen) 
 1 2 3 4 5 6 7 8 
Konzeption des Forschungsansatzes X     X  X 
Planung der Untersuchungen X        
Datenerhebung X X     X  
Datenanalyse und Interpretation X X X X X    
Schreiben des Manuskripts X X  X X X X X 
Vorschlag Anrechnung 
Publikationsäquivalent 
1.0        
 
 
Publications| 70 
 
Publications| 71 
 
 
Publications| 72 
 
Publications| 73 
 
 
Publications| 74 
 
Publications| 75 
 
 
Publications| 76 
 
Publications| 77 
 
 
Publications| 78 
 
Publications| 79 
 
 
Publications| 80 
 
Publications| 81 
 
 
Publications| 82 
 
Publications| 83 
 
 
Publications| 84 
 
Publications| 85 
 
 
 
Publications| 86 
 
  
Curriculum vitae| 88 
 
  
List of publications and conference contributions| 89 
 
 
List of publications and conference contributions  
Peer-reviewed publications 
1.  
J. Bec, H. Xie, D. R. Yankelevich, F. Zhou, Y. Sun, N. Ghata, R. Aldredge, and L. 
Marcu, "Design, construction, and validation of a rotary multifunctional 
intravascular diagnostic catheter combining multispectral fluorescence 
lifetime imaging and intravascular ultrasound," Journal of Biomedical Optics 
17, 106012–1 (2012). 
2.  
Y. Sun, H. Xie, J. Liu, M. Lam, A. J. Chaudhari, F. Zhou, J. Bec, D. R. Yankelevich, 
A. Dobbie, S. L. Tinling, R. F. Gandour-Edwards, W. L. Monsky, D. Gregory 
Farwell, and L. Marcu, "In vivo validation of a bimodal technique combining 
time-resolved fluorescence spectroscopy and ultrasonic backscatter 
microscopy for diagnosis of oral carcinoma," Journal of Biomedical Optics 17, 
116003–116003 (2012). 
3.  
H. Xie, J. Bec, J. Liu, Y. Sun, M. Lam, D. R. Yankelevich, and L. Marcu, 
"Multispectral scanning time-resolved fluorescence spectroscopy (TRFS) 
technique for intravascular diagnosis," Biomed. Opt. Express 3, 1521–1533 
(2012). 
4.  
J. Bec, D. M. Ma, D. R. Yankelevich, J. Liu, W. T. Ferrier, J. Southard, and L. 
Marcu, "Multispectral fluorescence lifetime imaging system for intravascular 
diagnostics with ultrasound guidance: in vivo validation in swine arteries," 
Journal of Biophotonics n/a-n/a (2013). 
5.  
H. Fatakdawala, S. Poti, F. Zhou, Y. Sun, J. Bec, J. Liu, D. R. Yankelevich, S. P. 
Tinling, R. F. Gandour-Edwards, D. G. Farwell, and L. Marcu, "Multimodal in 
vivo imaging of oral cancer using fluorescence lifetime, photoacoustic and 
ultrasound techniques," Biomed. Opt. Express 4, 1724–1741 (2013). 
6.  
C. Li, K. Di, J. Bec, and S. R. Cherry, "X-ray luminescence optical tomography 
imaging: experimental studies," Opt. Lett. 38, 2339–2341 (2013). 
7.  
A. Ferrero, Q. Peng, J. Zhou, G. Burkett, J. Bec, P. Gazi, M. G. B. Sumanasena, F. 
Godinez, J. Boone, and R. Badawi, "Performance characterization of a new 
generation breast and extremity PET/CT scanner," Journal of Nuclear 
Medicine 55, 2144–2144 (2014). 
8.  
N. Ghata, R. C. Aldredge, J. Bec, and L. Marcu, "Computational analysis of the 
effectiveness of blood flushing with saline injection from an intravascular 
diagnostic catheter," International Journal for Numerical Methods in 
Biomedical Engineering n/a-n/a (2014). 
9.  
D. Ma, J. Bec, D. R. Yankelevich, D. Gorpas, H. Fatakdawala, and L. Marcu, 
"Rotational multispectral fluorescence lifetime imaging and intravascular 
List of publications and conference contributions| 90 
 
ultrasound: bimodal system for intravascular applications," Journal of 
Biomedical Optics 19, 066004–066004 (2014). 
10.  
D. R. Yankelevich, D. Ma, J. Liu, Y. Sun, Y. Sun, J. Bec, D. S. Elson, and L. Marcu, 
"Design and evaluation of a device for fast multispectral time-resolved 
fluorescence spectroscopy and imaging," Review of Scientific Instruments 85, 
(2014). 
11.  
A. Z. Kyme, K. Gong, M. S. Judenhofer, J. Bec, J. Du, J. Qi, S. R. Cherry, and S. R. 
Meikle, "Open-field mouse brain PET: Design considerations and detector 
development," 2015 IEEE Nuclear Science Symposium and Medical Imaging 
Conference (NSS/MIC) 1–3 (2015). 
12.  
J. Bec, D. Ma, D. Yankelevich, W. T. Ferrier, J. Southard, and L. Marcu, "In vivo 
high speed multispectral fluorescence lifetime imaging (FLIm) of swine 
coronary arteries," in Optics in the Life Sciences, OSA Technical Digest 
(Online) (Optical Society of America, 2015), p. BW3A.6. 
13.  
S. Dochow, D. Ma, I. Latka, T. Bocklitz, B. Hartl, J. Bec, H. Fatakdawala, E. 
Marple, K. Urmey, S. Wachsmann-Hogiu, M. Schmitt, L. Marcu, and J. Popp, 
"Combined fiber probe for fluorescence lifetime and Raman spectroscopy," 
Analytical and bioanalytical chemistry 407, 8291–8301 (2015). 
14.  
J. Du, J. P. Schmall, K. Di, Y. Yang, M. Judenhofer, J. Bec, S. Buckley, C. Jackson, 
and S. R. Cherry, "Design and optimization of a high-resolution PET detector 
module for small-animal PET based on a 12 × 12 silicon photomultiplier 
array," Biomedical Physics & Engineering Express 1, 045003 (2015). 
15.  
H. Fatakdawala, D. Gorpas, J. W. Bishop, J. Bec, D. Ma, J. A. Southard, K. B. 
Margulies, and L. Marcu, "Fluorescence Lifetime Imaging Combined with 
Conventional Intravascular Ultrasound for Enhanced Assessment of 
Atherosclerotic Plaques: an Ex Vivo Study in Human Coronary Arteries," 
Journal of Cardiovascular Translational Research (2015). 
16.  
D. Gorpas, H. Fatakdawala, J. Bec, Dinglong Ma, D. R. Yankelevich, Jinyi Qi, and 
L. Marcu, "Fluorescence Lifetime Imaging and Intravascular Ultrasound: Co-
Registration Study Using Ex Vivo Human Coronaries," Medical Imaging, 
IEEE Transactions on 34, 156–166 (2015). 
17.  
D. Ma, J. Bec, D. Gorpas, D. Yankelevich, and L. Marcu, "Technique for real-time 
tissue characterization based on scanning multispectral fluorescence lifetime 
spectroscopy (ms-TRFS)," Biomed. Opt. Express 6, 987–1002 (2015). 
18.  
D. Gorpas, D. Ma, J. Bec, D. Yankelevich, and L. Marcu, "Real-Time Visualization 
of Tissue Surface Biochemical Features Derived from Fluorescence Lifetime 
Measurements," IEEE Transactions on Medical Imaging PP, 1–1 (2016). 
19.  
Y. Yang, J. Bec, J. zhou, M. Zhang, M. S. Judenhofer, X. Bai, K. Di, Y. Wu, M. 
Rodriguez, P. Dokhale, K. Shah, R. Farrell, J. Qi, and S. R. Cherry, "A high 
List of publications and conference contributions| 91 
 
 
resolution prototype small-animal PET scanner dedicated to mouse brain 
imaging," Journal of Nuclear Medicine (2016). 
20.  
J. Bec, J. E. Phipps, D. Gorpas, D. Ma, H. Fatakdawala, K. B. Margulies, J. A. 
Southard, and L. Marcu, "In vivo label-free structural and biochemical 
imaging of coronary arteries using an integrated ultrasound and multispectral 
fluorescence lifetime catheter system," Scientific Reports 7, 8960 (2017). 
21.  
A. Z. Kyme, M. S. Judenhofer, K. Gong, J. Bec, A. Selfridge, J. Du, J. Qi, S. R. 
Cherry, and S. R. Meikle, "Open-field mouse brain PET: design optimisation 
and detector characterisation," Physics in Medicine & Biology 62, 6207–6225 
(2017). 
22.  
B. E. Sherlock, J. E. Phipps, J. Bec, and L. Marcu, "Simultaneous, label-free, 
multispectral fluorescence lifetime imaging and optical coherence tomography 
using a double-clad fiber," Opt. Lett. 42, 3753–3756 (2017). 
23.  
X. Zhang, E. Berg, J. Bec, M. Judenhofer, M. Kapusta, M. Schmand, M. Casey, R. 
Badawi, S. Cherry, and J. Qi, "First Pre-Clinical Study of Total-Body Dynamic 
PET Imaging using the mini-EXPLORER Scanner," Journal of Nuclear 
Medicine 58, 394–394 (2017). 
24.  
E. Berg, X. Zhang, J. Bec, M. S. Judenhofer, B. Patel, Q. Peng, M. Kapusta, M. 
Schmand, M. E. Casey, A. F. Tarantal, J. Qi, R. D. Badawi, and S. R. Cherry, 
"Development and Evaluation of mini-EXPLORER: A Long Axial Field-of-
View PET Scanner for Nonhuman Primate Imaging," J Nucl Med 59, 993–998 
(2018). 
25.  
D. Gorpas, P. Davari, J. Bec, M. A. Fung, L. Marcu, D. G. Farwell, and N. Fazel, 
"Time-resolved fluorescence spectroscopy for the diagnosis of oral lichen 
planus," Clinical and Experimental Dermatology 43, 546–552 (2018). 
26.  
J. L. Lagarto, J. E. Phipps, L. Faller, D. Ma, J. Unger, J. Bec, S. Griffey, J. Sorger, 
D. G. Farwell, and L. Marcu, "Electrocautery effects on fluorescence lifetime 
measurements: An in vivo study in the oral cavity," Journal of Photochemistry 
and Photobiology B: Biology 185, 90–99 (2018). 
27.  
A. Alfonso-Garcia, J. Bec, S. Sridharan, B. Hartl, J. Unger, M. Bobinski, M. 
Lechpammer, F. Girgis, J. Boggan, and L. Marcu, "Real-time augmented 
reality for delineation of surgical margins during neurosurgery using 
autofluorescence lifetime contrast," Journal of Biophotonics 0, e201900108 
(2019). 
28.  
A. Alfonso-Garcia, C. Li, J. Bec, D. Yankelevich, L. Marcu, and B. Sherlock, "Fiber-
based platform for synchronous imaging of endogenous and exogenous 
fluorescence of biological tissue," Opt. Lett. 44, 3350–3353 (2019). 
29.  
List of publications and conference contributions| 92 
 
J. Bec, C. Li, and L. Marcu, "Broadband, freeform focusing micro-optics for a side-
viewing imaging catheter," Opt. Lett. 44, 4961–4964 (2019). 
30.  
D. Gorpas, J. Phipps, J. Bec, D. Ma, S. Dochow, D. Yankelevich, J. Sorger, J. Popp, 
A. Bewley, R. Gandour-Edwards, L. Marcu, and D. G. Farwell, 
"Autofluorescence lifetime augmented reality as a means for real-time robotic 
surgery guidance in human patients," Scientific Reports 9, 1187 (2019). 
31.  
B. E. Sherlock, C. Li, X. Zhou, A. Alfonso-Garcia, J. Bec, D. Yankelevich, and L. 
Marcu, "Multiscale, multispectral fluorescence lifetime imaging using a 
double-clad fiber," Opt. Lett. 44, 2302–2305 (2019). 
 
  
List of publications and conference contributions| 93 
 
 
Conference presentations 
1.  
J. Bec, H.Xi, D. R. Yankelevitch, F. Zhou, Y. Sun, N. Ghata, R. Aldredge, and L. 
Marcu, "Design, construction, and validation of a multimodal intravascular 
diagnostic catheter combining IVUS and fluorescence lifetime spectroscopy 
detection channels," 7883D-78, Photonics West (2011), Oral presentation.  
 
3. 
J. Bec, D. Ma, D. R. Yankelevitch, and L. Marcu, "Design and validation of a small-
profile rotational catheter for combined fluorescence lifetime imaging (FLIm) 
and intravascular ultrasound (IVUS) imaging of coronary arteries," 8565-135, 
Photonics West (2013), Oral presentation.  
4.  
J. Bec, D. Ma, D. R. Yankelevitch, D. Gorpas, W.T. Ferrier, J.A. Southard, and L. 
Marcu, "In-vivo validation of fluorescence lifetime imaging (FLIm) of coronary 
arteries in swine," 9303-523, Photonics West (2015), Oral presentation.  
5.  
J. Bec, D. Ma, D. R. Yankelevitch, D. Gorpas, W.T. Ferrier, J.A. Southard, and L. 
Marcu, " In vivo high-speed multispectral fluorescence lifetime imaging 
(FLIm) of swine coronary arteries," 2209002, OSA: Optics in the Life Sciences 
Congress (2015), Oral presentation.  
6.  
J. Bec, D. Gorpas, H. Fatakdawala, J.E. Phipps, D. Ma, D. R. Yankelevitch, J.A. 
Southard, and L. Marcu, " In-vivo validation of a multi-modal fluorescence 
lifetime imaging (FLIm)-IVUS catheter in swine coronary arteries," 9689-103, 
Photonics West (2016), Oral presentation.  
7.  
J. Bec, J.E. Phipps, K. B. Margulies, and L. Marcu, " Multivariate analysis of 
multispectral fluorescence lifetime imaging (FLIm) data: application to 
atherosclerotic plaque staging," 10042-24, Photonics West (2017), Oral 
presentation.  
 
8.  
J. Bec, J.E. Phipps, J. Unger, D. Vela, L. M. Buja, J.A. Southard, K.B. Margulies, 
and L. Marcu," FLIm and IVUS see things that OCT and NIRS do not," Optics 
in Cardiology (2017), Oral presentation.  
9.  
J. Bec, C. Li, B. Sherlock, and L. Marcu, " Freeform broad-band focusing micro 
optics: application to catheter-based fluorescence lifetime imaging of coronary 
arteries," 10471-3, Photonics West (2018), Oral presentation.  
10.  
J. Bec, D. Henry, R.D. Badawi and S.R.Cherry “ Optical motion tracking for use 
with the EXPLORER total-body PET scanner” 1717, SNMMI (2018), Oral 
presentation.  
11.  
J. Bec, C. Li, and L. Marcu, " Systematic assessment of FLIm signature of ex-vivo 
human coronary atherosclerotic lesions: towards label-free quantitative 
List of publications and conference contributions| 94 
 
assessment of lesion composition," 10855-12, Photonics West (2019), Oral 
presentation.  
 
 
  
List of publications and conference contributions| 95 
 
 
 
 
Acknowledgments 
I want to thank Prof. Dr. Laura Marcu for the opportunity to work in her research 
lab and for her continuing support and guidance over the last ten years. I also 
would like to thank Prof. Dr. Jürgen Popp for giving me the opportunity to work 
on my doctoral thesis in collaboration with his group. 
I want to thank Dr. Diego Yankelevitch, Dr. Dinglong “Michael” Ma, Dr. Dimitris 
Gorpas, Dr. Hussein Fatakdawala, Dr. Jennifer Phipps, Dr. Jakob Unger, Dr. 
Benjamin Sherlock, Cai Li for the many discussions and fruitful collaboration over 
the years, pushing intravascular FLIm applications forward 
My gratitude also goes to all past and present members of the UC Davis 
biophotonics Laboratory/ Marcu Lab with which I have enjoyed collaborating over 
the years on such a wide variety of research projects. The friendly and positive 
working environment you all helped to provide was key to navigate the sometimes 
thrilling, and sometimes trying times of academic research. 
I would like to extend my thanks to our external collaborators. Dr. Jeffrey 
Southard, Dr. Bill Ferrier, and Dr. Deborah Vela’s dedication and expertise in the 
fields of cardiovascular medicine, veterinary medicine, and pathology have been 
key to this work. 
On a personal note, I would like to thank all my dear friends from Grenoble, Lyon, 
Turin, Modena, Paris, Davis, Jena and other places where I was fortunate to get 
to spend some time. 
Above all, I would like to thank Dr. Emilie Roncali, outstanding scientist and 
amazing life partner. I cannot think of a better person to deal with the challenges 
and enjoy the rewards of two academic careers and three rambunctious kids. We 
got this! 
List of publications and conference contributions| 96 
 
  
Erklärungen| 97 
 
 
 
Erklärungen 
 
Selbstständigkeitserklärung 
Ich erkläre, dass ich die vorliegende Arbeit selbstständig und unter Verwendung 
der angegebenen Hilfsmittel, persönlichen Mitteilungen und Quellen angefertigt 
habe. 
 
Julien BEC   ___________________________________________________ 
     (Datum)   (Ort)   (Unterschrift) 
 
 
 
 
Erklärung zu den Eigenanteilen des Promovenden/der Promovendin sowie der 
weiteren Doktoranden/Doktorandinnen als Koautoren an den Publikationen und 
Zweitpublikationsrechten bei einer kumulativen Dissertation 
Für alle in dieser kumulativen Dissertation verwendeten Manuskripte liegen die 
notwendigen Genehmigungen der Verlage („Reprint permissions“) für die 
Zweitpublikation vor. 
Die Co-Autoren der in dieser kumulativen Dissertation verwendeten Manuskripte 
sind sowohl über die Nutzung, als auch über die oben angegebenen Eigenanteile 
informiert und stimmen dem zu (es wird empfohlen, diese grundsätzliche 
Zustimmung bereits mit Einreichung der Veröffentlichung einzuholen bzw. die 
Gewichtung der Anteile parallel zur Einreihung zu klären).Die Anteile der Co-
Autoren an den Publikationen sind in diesem Kapitel aufgeführt. 
 
 
 
Julien BEC       ___________________________________________________ 
     (Datum)   (Ort)   (Unterschrift) 
 
Erklärungen| 98 
 
 
  
Erklärungen| 99 
 
 
 
Einverständniserklärung des Betreuers 
Ich bin mit der Abfassung der Dissertation als publikationsbasiert, d.h. kumulativ, 
einverstanden und bestätige die vorstehenden Angaben. Eine entsprechend 
begründete Befürwortung mit Angabe des wissenschaftlichen Anteils des 
Doktoranden/der Doktorandin an den verwendeten Publikationen werde ich 
parallel an den Rat der Fakultät der Chemisch Geowissenschaftlichen Fakultät 
richten. 
 
 
 
Prof. Dr. Jürgen Popp ___________________________________________________ 
     (Datum)   (Ort)   (Unterschrift)  
 
 
 
 
 
